

STN SEARCH TRANSCRIPT 10/645312

"DELOMBAERT CRF ANTAGS"

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623ECT

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR 7):2

***** Welcome to STN International *****


NEWS 1 Web Page URL for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 28 PATDPATFULL - New display fields provide for legal status
data from IPADOC
NEWS 4 FEB 28 BASS - Current-awareness alerts (SDIs) available
NEWS 5 MAR 02 GBFULL: New full-text patent database on STN
NEWS 6 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 8 MAR 22 KOREPAT now updated monthly; patent information enhanced
NEWS 9 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS 10 MAR 22 PATDPATFULL - New patent database available
NEWS 11 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS 12 APR 04 EPPFULL enhanced with additional patent information and new
fields
NEWS 13 APR 04 EMBASE - Database reloaded and enhanced
NEWS 14 APR 18 New CAS Information Use Policies available online
NEWS 15 APR 25 Patent searching, including current-awareness alerts (SDIs),
based on application date in CA/Capplus and USPATFULL/USPAT2
may be affected by a change in filing date for U.S.
applications.
NEWS 16 APR 28 Improved searching of U.S. Patent Classifications for
U.S. patent records in CA/Capplus
NEWS 17 MAY 23 GBFULL enhanced with patent drawing images
NEWS 18 MAY 23 REGISTRY has been enhanced with source information from
CHEMCATS
NEWS 19 JUN 06 STN Patent Forums to be held in June 2005
NEWS 20 JUN 06 The Analysis Edition of STN Express with Discover!
(Version 8.0 for Windows) now available
NEWS 21 JUN 13 RUSSIPAT: New full-text patent database on STN
NEWS 22 JUN 13 EPPFULL enhanced with patent drawing images
NEWS 23 JUN 20 MEDICAT to be removed from STN
NEWS 24 JUN 27 MARPAT displays enhanced with expanded G-group definitions
and text labels

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V6.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer



chain nodes :
17 19
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
3-19 6-7 12-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
3-19 6-7 7-8 7-12 8-9 9-10 10-11 11-12 12-17
normalised bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 7 :

G1:C,N

G2:CH,X,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO

G3:O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 17:CLASS 19:CLASS

L1 STRUCTURE UPLOADED

--> que L1

L2 QUE L1

--> D L1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

--> S L2

SAMPLE SEARCH INITIATED 14:42:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 251 TO ITERATE

agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 14:42:20 ON 29 JUN 2005

--> FILE REG	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:42:30 ON 29 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JUN 2005 HIGHEST KN 053177-57-8
DICTIONARY FILE UPDATES: 28 JUN 2005 HIGHEST KN 053177-57-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registries.html>

-->Testing the current file..... screen

ENTER SCREEN EXPRESSION OR (END):end

-->
Uploading C:\Program Files\Stnexp\Queries\DELOMBAERT CRF ANTAGS.str

100.0% PROCESSED 251 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4070 TO 5970
PROJECTED ANSWERS: 608 TO 1472

L3 50 SEA SSS SAM L1

--> S L3 SSS FULL
FULL SEARCH INITIATED 14:44:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5294 TO ITERATE

100.0% PROCESSED 5294 ITERATIONS 978 ANSWERS
SEARCH TIME: 00.00.01

L4 978 SEA SSS FUL L1

--> FILE CAPLUS	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	162.19	162.40

FILE 'CAPLUS' ENTERED AT 14:44:08 ON 29 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 Jun 2005 VOL 143 ISS 1
FILE LAST UPDATED: 28 Jun 2005 (20050628/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

--> S L4
L5 S1 L4

--> D 1-51

L5 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:293493 CAPLUS
DN 142:355283

T1 Preparation of triazolopyrazines, pyrazolopyrimidines, pyrazolopyridines,
pyrazolopyrazines and related compounds as corticotropin releasing factor
(CRF) receptor ligands.

IN Hodgetts, Kevin J.; John, Stanley; Moorcroft, Neil; Shutake, Greg; Kaiser,
Bernd; Yamaguchi, Yasuchika; Ge, Ping; Korvath, Raymond F.

PA Neurogen Corporation, USA; Aventis Pharmaceuticals Inc.

SO PCT Int. Appl., 187 pp.
CODEN: PIXKD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2005028480 A2 20050331 WO 2004-0528663 20040903
WO 2005028480 A3 20050602
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GR, GE, GH, GM, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MH, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SN, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GE, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG
US 2005070542 A1 20050331 US 2004-933709 20040903
PRAI US 2003-500033P P 20030903
OS MARPAT 142:355283

LS ANSWER 2 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:238985 CAPLUS
DN 142:316863
TI Preparation of heteroaryl fused pyridines, pyrazines, and pyrimidines as CRP-1 receptor ligands
IN Ge, Ping; Horvath, Raymond F.; Zhang, Lu Yan; Yamaguchi, Yasuchika; Kaiser, Bernd; Zhang, Yuechun; Zhang, Suoning; Zhao, He; John, Stanley; Moorcroft, Neil; Shuteke, Greg
PA Neurogen Corporation, USA; Aventis Pharmaceuticals Inc.
SO PCT Int. Appl., 290 pp.
CODEN: PIXKD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2005023806 A2 20050317 WO 2004-0528899 20040903
WO 2005023806 A3 20050602
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GR, GE, GH, GM, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MH, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SN, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GE, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG
US 2005113279 A1 20050526 US 2004-933834 20040903
PRAI US 2003-500414P P 20030905
OS MARPAT 142:316863

LS ANSWER 3 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:179880 CAPLUS
TI Palladium-Catalyzed Cross-Coupling Reactions of Pyridylboronic Acids with Heteroaryl Halides Bearing a Primary Amine Group: Synthesis of Highly Substituted Bipyridines and Pyrazinopyridines. [Erratum to document cited in CA142:198022]
AU Thompson, Amy E.; Hughes, Gregory; Batsanov, Andrei S.; Bryce, Martin R.;

PA Biofocus Discovery Ltd., UK
SO Brit. Pat. Appl., 133 pp.
CODEN: BAYXDU
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI GB 2400101 A1 20041006 GB 2003-7214 20030328
WO 2004085409 A2 20041007 WO 2004-GB1399 20040326
WO 2004085409 A3 20041223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GR, GE, GH, GM, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MH, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SN, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GE, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG
PRAI GB 2003-7214 A 20030328
OS MARPAT 141:314349
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 7 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:759828 CAPLUS
DN 141:260774
TI Preparation of pyrazinecarboxamide compounds as inhibitors of transforming growth factor (TGF) signaling pathway
IN Munchhof, Michael J.
PA Pfizer Inc., USA
SO U.S. Pat. Appl. Publ., 26 pp.
CODEN: USYXCO
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 2004180905 A1 20040916 US 2004-798198 20040310
US 2004080982 A1 20040923 WO 2004-1B581 20040223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GR, GE, GH, GM, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MH, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SN, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GE, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG
PRAI US 2003-453784P P 20030311
OS MARPAT 141:260774

LS ANSWER 8 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:515493 CAPLUS
DN 141:71565
TI Preparation of pyrazines and related compounds as glucokinase activators for the treatment of type II diabetes
IN Chen, Shaoqing; Corbett, Wendy Lee; Guertin, Kevin Richard; Haynes, Nancy-Elleen; Kester, Robert Francis; Memmola, Francis A.; Mischke, Steven Gregory; Olan, Yitain; Sarabu, Ramakanth; Scott, Nathan Robert; Thakkar,

Pary, Paul R.; Tarbit, Brian
CS Department of Chemistry, University of Durham, Durham, DH1 1LE, UK
SO Journal of Organic Chemistry (2005), 70(7), 2884
CODEN: JOCEAR; ISSN: 0022-3263
PB American Chemical Society
DT Journal; Errata
LA English
LS ANSWER 4 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:1067792 CAPLUS
DN 142:198022
TI Palladium-Catalyzed Cross-Coupling Reactions of Pyridylboronic Acids with Heteroaryl Halides Bearing a Primary Amine Group: Synthesis of Highly Substituted Bipyridines and Pyrazinopyridines
AU Thompson, Amy E.; Hughes, Gregory; Batsanov, Andrei S.; Bryce, Martin R.; Pary, Paul R.; Tarbit, Brian
CS Department of Chemistry, University of Durham, Durham, DH1 1LE, UK
SO Journal of Organic Chemistry (2005), 70(1), 388-390
CODEN: JOCEAR; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 5 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:896174 CAPLUS
DN 141:410966
TI Preparation of pyrazineamine derivative as CRP1 receptor antagonists
IN Corbett, Jeffrey W.; Ennis, Michael D.; Frank, Kristine E.; Fu, Jian-Min; Hoffman, Robert L.; Verhoeven, Patrick R.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 57 pp.
CODEN: PIXKD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2004092921 A1 20041118 WO 2004-1B1553 20040505
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GR, GE, GH, GM, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MH, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SN, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GE, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG
US 2005038040 A1 20050217 US 2004-840485 20040506
PRAI US 2003-469466P P 20030509
OS MARPAT 141:410966
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 6 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:812360 CAPLUS
DN 141:314349
TI Preparation of libraries of compounds (e.g. pyridines, pyrazines, imidazopyrazines) capable of binding to the active site of protein kinases
IN Harris, John; Church, Nicola; Proud, Andrew; Kling, Marcel; Vickery, Benjamin D.

Kabitij Chhabilbhai
PA F. Hoffmann-La Roche Ag, Swits.
SO PCT Int. Appl., 243 pp.
CODEN: PIXKD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2004052869 A1 20040624 WO 2003-EP14055 20031211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GR, GE, GH, GM, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MH, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SN, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GE, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG
US 2004147748 A1 20040729 US 2003-732838 20031210
PRAI US 2003-432806P P 20031212
US 2003-524531P P 20031124
OS MARPAT 141:71565

LS ANSWER 9 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:182851 CAPLUS
DN 140:217643
TI Preparation of 5-substituted-2-arylpyrazines as modulators of CRF receptors
IN Yoon, Taeyoung; Ge, Ping; Delombaert, Stephane; Horvath, Raymond
PA Neurogen Corporation, USA
SO PCT Int. Appl., 137 pp.
CODEN: PIXKD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2004018437 A1 20040304 WO 2003-US26141 20030820
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GR, GE, GH, GM, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MH, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SN, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GE, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG
CA 2496197 AA 20040304 CA 2003-2496197 20030820
US 2004106620 A1 20040603 US 2003-645312 20030820
PRAI US 2002-405013P P 20020820
WO 2003-US26141 F 20020820
OS MARPAT 140:217643
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 10 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:604898 CAPLUS
DN 140:128431
TI Preparation of pyrazine and quinoxaline derivatives as chemokine receptor CCR4 antagonists and medicinal use thereof
IN Hashizata, Hiroshi; Kokubo, Masaya; Shibayama, Shiro; Tada, Hideaki;

APPLICANTS

10/645312

Sagawa, Kenji
FA Qno Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 353 pp.
CODEN: PIXND2
DT Patent
LA Japanese
FAM.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004007472	A1	20040122	WO 2003-JP8654	20030708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PA, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SJ, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CN, CO, GU, GW, ML, MR, NE, SN, TD, TO				
EP 1541563	A1	20050615	EP 2003-764137	20030708
R: AT, BE, CH, DE, DK, EE, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI JP 2002-200879	A	20020710		
WO 2003-JP8654	W	20030708		
OS MARPAT 140128431				
RE.CNT 9				
THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD				
ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L5 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:20338 CAPLUS
DN 140:77031
TI N-heterocyclic-N'-heterocycliureas as neuropeptide Y Y5 receptor antagonists
IN Stamford, Andrew; Dong, Youhao; McCobbie, Stuart W.; Wu, Yusheng
PA USA
SO U.S. Pat. Appl. Publ., 84 pp., Cont. in part of U.S. Ser. No. 26,651.
CODEN: USXYCO
DT Patent
LA English
FAM.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004006086	A1	20040108	US 2002-177345	20020620
US 2003050662	A1	20030320	US 2001-26651	20011218
FRAI US 2000-357308P	P	20001221		
US 2001-26651	A2	20011221		
OS MARPAT 140:77031				

L5 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:892800 CAPLUS
DN 139:395950
TI Preparation of substituted pyrazines as protein kinase modulators
IN Buhre, Chris A.; Baik, Tae-Gom; Ma, Sunghoon; Tesfai, Zeren; Wang, Longcheng; Co, Erick Wang; Epehteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tese R.; Nuss, John M.; Peto, Cseba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepf, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Eather; Forsyth, Timothy Patrick; Ruyh, Tai Phat; Mann, Grace; Mann, Larry Wayne; Takeuchi, Craig Stacy
PA Exelixis, Inc., USA
SO PCT Int. Appl., 468 pp.
CODEN: PIXND2
DT Patent
LA English
FAM.CNT 1

DN 139:6991
TI Preparation of substituted aryl pyrazine derivatives as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders
IN Verhoest, Patrick R.; Hoffman, Robert L.; Corbett, Jeffrey W.; Ennis, Michael D.; Frank, Kristine E.; Pu, Jian-Min
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 271 pp.
CODEN: PIXND2
DT Patent
LA English
FAM.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003045924	A1	20030605	WO 2002-US33642	20021115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PA, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, CN, CO, GU, GW, ML, MR, NE, SN, TD, TO				
CA 2467870	AA	20030605	CA 2002-2467870	20021115
US 2003144297	A1	20030731	US 2002-298193	20021115
EP 1446387	A1	20040818	EP 2002-780507	20021115
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR				
BR 2002014309	A	20041013	BR 2002-14309	20021115
US 2005049257	A1	20050303	US 2004-844004	20040512
PRAI US 2001-332052P	P	20011121		
US 2002-358546P	P	20020221		
US 2002-388282P	P	20020413		
US 2002-410378P	P	20020513		
US 2002-298193	A1	20021115		
WO 2002-US33642	W	20021115		
OS MARPAT 139:6991				
RE.CNT 5				
THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD				
ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L5 ANSWER 15 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:98493 CAPLUS
DN 139:159426
TI Synthesis, structure-activity relationship and in vitro evaluation of coelenterazine and coelenteramine derivatives as inhibitors of lipid peroxidation
AU Burton, Maggi; De Tollenaere, Catherine; Cavalier, Jean-Francois; Marchand, Cecile; Dussart, Frederique; Marchand-Brynaert, Jacqueline; Rees, Jean-Francois
CS Laboratory of Cell Biology, Institut des Sciences de la Vie, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
SO Free Radical Research (2003), 37(2), 145-158
CODEN: FRABER; ISSN: 1071-5762
PB Taylor & Francis Ltd.
DT Journal
LA English
OS CASREACT 139:159426
RE.CNT 21

THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LA English
FAM.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003093297	A2	20031113	WO 2003-US13869	20030502
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PA, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CN, CO, GU, GW, ML, MR, NE, SN, TD, TO				
CA 2484209	AA	20031113	CA 2003-2484209	20030502
EP 1501514	A2	20050202	EP 2003-728690	20030502
R: AT, BE, CH, DE, DK, EE, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI US 2003-277939P	P	20030503		
WO 2003-US13869	W	20030502		
OS MARPAT 139:395950				
L5 ANSWER 13 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN AN 2003:570968 CAPLUS DN 139:133585 TI Preparation of N-pyrazinylbenzenesulfonamides and their use in the treatment of chemokine mediated diseases such as asthma IN Baxter, Andrew; Johnson, Timothy; Kindon, Nicholas; Roberts, Bryan; Stocks, Michael PA AstraZeneca AB, Swed. SO PCT Int. Appl., 175 pp. CODEN: PIXND2 DT Patent LA English FAM.CNT 1				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003059893	A1	20030724	WO 2003-SE41	20030114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PA, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CN, CO, GU, GW, ML, MR, NE, SN, TD, TO				
CA 2472204	AA	20030724	CA 2003-2472204	20030114
EP 1467976	A1	20041020	EP 2003-700655	20030114
R: AT, BE, CH, DE, DK, EE, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 200306922	A	20041109	BR 2003-6922	20030114
PRAI SE 2002-119	A	20020116		
SE 2002-1857	A	20020617		
WO 2003-SE41	W	20030114		
OS MARPAT 139:133585				
RE.CNT 5				
THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD				
ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L5 ANSWER 14 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:434540 CAPLUS

DN 138:106713
TI Preparation of heterocyclic amines for the treatment of conditions associated with GSK3
IN Berg, Stefan; Hallberg, Sven
PA AstraZeneca AB, Swed.
SO PCT Int. Appl., 62 pp.
CODEN: PIXND2
DT Patent
LA English
FAM.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003004475	A1	20030116	WO 2002-SE1340	20020703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PA, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, CN, CO, GU, GW, ML, MR, NE, SN, TD, TO				
EP 1406977	A1	20040414	EP 2002-749475	20020703
R: AT, BE, CH, DE, DK, EE, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2004536110	T2	20041102	JP 2003-510642	20030703
US 2004186113	A1	20040523	US 2003-481699	20031222
PRAI SE 2001-2438	A	20010705		
WO 2002-SE1340	W	20020703		
OS MARPAT 138:106713				
RE.CNT 11				
THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD				
ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L5 ANSWER 17 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:42250 CAPLUS
DN 138:106712
TI Preparation of pyrazine-2-carboxamides as glycogen synthase kinase-3 (GSK3) inhibitors
IN Berg, Stefan; Hallberg, Sven
PA AstraZeneca AB, Swed.
SO PCT Int. Appl., 158 pp.
CODEN: PIXND2
DT Patent
LA English
FAM.CNT 1

THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD

R: AT, RE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
ER 2002010838 A 20040713 ER 2002-10838 20020703
JP 2005050515 T2 20050224 JP 2003-510640 20020703
PRAI SE 2001-2439 A 20010705
WO 2002-581339 W 20020703
OS MARPAT 138:10612
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:554265 CAPLUS
DN 137:243205
TI Comparison of the computer programs DEREK and TOPKAT to predict bacterial
mutagenicity
AU Carriello, Neal P.; Wilson, John D.; Britt, Ben R.; Wedd, David J.;
Burlinson, Brian; Gouber, Vijay
CS Safety Assessment, GlaxoSmithKline Inc., Research Triangle Park, NC,
27709, USA
SO Mutagenesis (2002), 17(4), 321-329
CODEN: MUTAEY; ISSN: 0267-8357
PB Oxford University Press
DT Journal
LA English
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:487401 CAPLUS
DN 137:47125
TI N-heteroaryl-N'-heterocyclylureas as neuropeptide Y Y5 receptor
antagonists
IN Stamford, Andrew W.; Dong, Youhao; McCombie, Stuart W.
PA Schering Corporation, USA
SO PCT Int. Appl., 127 pp.
CODEN: PIXKD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002049648	A1	20020627	WO 2001-US49302	20011217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MO, MU, MV, MW, MX, MY, MZ, NA, NI, NL, NO, NZ, PL, PT, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UY, VZ, ZA, ZM, ZW, AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LL, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ				

PA Glaxo Group Limited, UK
SO PCT Int. Appl., 23 pp.
CODEN: PIXKD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002000199	A1	20020103	WO 2001-GB29223	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GU, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NI, NL, NO, NZ, PL, PT, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UY, VZ, ZA, ZM, ZW, AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LL, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ				

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:10259 CAPLUS
DN 136:74643
TI Process for preparing and harvesting crystalline pharmaceutical particles
IN Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis
PA Glaxo Group Ltd., UK
SO PCT Int. Appl., 20 pp.
CODEN: PIXKD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002000198	A1	20020103	WO 2001-GB29222	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GU, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NI, NL, NO, NZ, PL, PT, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UY, VZ, ZA, ZM, ZW, AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LL, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ				

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:859509 CAPLUS
DN 136:270314

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:183584 CAPLUS
DN 137:41243
TI N-O glucuronidation: a major human metabolic pathway in the elimination of
two novel anti-convulsant drug candidates
AU Ismail, I. M.; Dear, G. J.; Roberts, A. D.; Plumb, R. S.; Ayrton, J.;
Sweatman, B. C.; Bowers, G. D.
CS Structural Identification Group, GlaxoSmithKline Research and Development,
Ware, SG12 0DP, UK
SO Xenobiotica (2002), 32(1), 29-43
CODEN: XENBHI; ISSN: 0049-8254
PB Taylor & Francis Ltd.
DT Journal
LA English
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:10467 CAPLUS
DN 136:69823
TI Preparation of imidazole derivatives or salts thereof and drugs containing
the derivatives or the salts
IN Komuro, Fujiko; Nagao, Yoshihiro; Isomae, Kazuo; Ohtsuka, Mari; Takahashi,
Yoshiyuki; Ishii, Pami; Hirota, Hiroaki; Kuroyuki, Takeda, Sunao; Kawamoto,
Horiyuki; Honda, Haruyoshi; Sato, Shunro
PA Sep Co., Ltd., Japan
SO PCT Int. Appl., 53 pp.
CODEN: PIXKD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002000648	A1	20020103	WO 2001-JP4836	20010609
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MO, MU, MV, MW, MX, MY, MZ, NA, NI, NL, NO, NZ, PL, PT, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UY, VZ, ZA, ZM, ZW, AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LL, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ				

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:10260 CAPLUS
DN 136:74644
TI Novel process for preparing and harvesting crystalline pharmaceutical
particles
IN Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis

TI Fluorescence properties of phenolate anions of coelenteramide analogues:
the light-emitter structure in aequorin bioluminescence
AU Imai, Yuko; Shibata, Takuya; Maki, Shojiro; Nawa, Haruki; Chashi, Mamoru;
Hirano, Takashi
CS Department of Applied Physics and Chemistry, The University of
Electro-Communications, Chofu, Tokyo, 182-8585, Japan
SO Journal of Photochemistry and Photobiology, A: Chemistry (2001), 146(1-2),
95-107
CODEN: JPPCEJ; ISSN: 1010-6030
PB Elsevier Science S.A.
DT Journal
LA English
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 25 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:833264 CAPLUS
DN 135:357945
TI Two-step process for the preparation of 2,6-diamino-3-(2,3,5-
trichlorophenyl)pyrazine
IN Edsley, Dean David; Kennedy, Andrew
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 11 pp.
CODEN: PIXKD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001085674	A1	20011115	WO 2001-GB1929	20010502
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GU, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NI, NL, NO, NZ, PL, PT, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UY, VZ, ZA, ZM, ZW, AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LL, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ				

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:617988 CAPLUS
DN 135:180787
TI Preparation of substituted arylpyrazines and their binding with CRP1
receptors
IN Yoon, Taeyoung; Ge, Ping; Horvath, Raymond F.; De Lombaert, Stephane;
Hodgetts, Kevin J.; Doller, Dario; Zhang, Cunyu
PA Neurogen Corporation, USA
SO PCT Int. Appl., 193 pp.
CODEN: PIXKD2
DT Patent
LA English
FAN.CNT 1

L5 ANSWER 40 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:483377 CAPLUS
DN 121:83377
TI (Biphenyl)pyrazines for liquid crystalline media
IN Brown, John William; Hurst, Derek Thomas; O'Donovan, Jacqueline Patricia;
Coates, David; Greenfield, Simon; Goulding, Mark John; Gray, George
William
FA Merck Patent GmbH, Germany
PO Brit. UK Pat. Appl., 40 pp.

LS ANSWER 43 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1992:571380 CAPLUS
DN 117:171380
TI Metallation of diazines. VI. Metallation of pivaloylaminopyrazine and
N-tert-butylpyrazinamide. Unusual regioselectivity in the metatation

reaction.
AU Turk, A.; Pie, N.; Trohay, D.; Kdsi, B.; Oequeiner, G.
CS Lab. Chim. Org. Fine Heterocyclique, INSA, Mt. St. Aignan, 76131, Fr.
SO Journal of Heterocyclic Chemistry (1992), 29(4), 699-702
CODEN: JHCCAD; ISSN: 0022-152X

DT Journal
LA English
OS CASREACT 117:171380

L5 ANSWER 44 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1982:35307 CAPLUS
DN 96:35307
TI 1-(Meno-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
IN Miesel, John L.
PA Eli Lilly and Co., USA
SO U.S., 15 pp. Cont.-in-part of U.S. Ser. No. 881,300, abandoned.
CODEN: USXXAM

DT Patent
LA English
FAM.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4293552	A	19811006	US 1979-42393	19790731
PRAI US 1978-881300	A2	19780227		

L5 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1980:420777 CAPLUS
DN 93:220777
TI Substituted 2-aminopyrazines
IN Barnett, Charles J.; Esmick, Thomas L.; Hoving, Richard C.
PA Eli Lilly and Co., USA
SO U.S., 11 pp.
CODEN: USXXAM

DT Patent
LA English
FAM.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4211870	A	19800708	US 1978-27630	19780406
DK 8001442	A	19801007	DK 1980-1442	19800402
FI 8001056	A	19801007	FI 1980-1056	19800402
AU 8057102	A1	19801009	AU 1980-57102	19800402
FR 2453159	A1	19801031	FR 1980-7457	19800402
BR 8002079	A	19801125	BR 1980-2079	19800402
ES 490287	A	19810516	ES 1980-490287	19800402
CS 215055	P	19800730	CS 1980-2293	19800402
CA 1157860	A1	19811129	CA 1980-349061	19800402
BE 882608	A1	19801003	BE 1980-9771	19800403
EP 18144	A1	19801029	EP 1980-301085	19800403
R: DE, GB, NL, SE				
GB 2046751	A	19801119	GB 1980-11363	19800403
DE 2046751	A1	19801119		19800403
UD 150057	C	19810812	UD 1980-220207	19800403
ZA 8002005	A	19811125	ZA 1980-2005	19800403
HU 26151	O	19800928	HU 1980-817	19800403
SU 932989	A3	19820530	SU 1980-2902455	19800404
RO 79384	P	19820625	RO 1980-100722	19800404
JP 55141473	A2	19801105	JP 1980-45114	19800405
PRAI US 1979-27630	A	19790406		

L5 ANSWER 46 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1979:540598 CAPLUS
DN 91:140598
TI 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas

DD 141831 C 19800521 DD 1978-206203 19780622
PD 143721 C 19800910 DD 1978-213690 19780622
IL 115711 B1 19810430 PL 1978-207831 19780622
ES 471879 A1 19790201 ES 1978-471879 19780719
CA 1103251 A1 19810616 CA 1978-308083 19780725
FR 2398739 A1 19790223 FR 1978-32550 19781117
FR 2398739 B1 19811105
IL 64216 A1 19821231 IL 1979-64216 19790615
AT 8101716 A 19820415 AT 1981-1716 19810415
DK 8103054 A 19810709 DK 1981-3054 19810709
SE 8303206 A 19830607 SE 1983-3206 19830607
PRAI US 1977-26093 A 19770622
US 1977-819639 A 19770727
IL 1978-54928 A3 19780619
AT 1978-4456 A 19780619
GB 1978-27260 A 19780619
DK 1978-2793 A 19780621

L5 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1978:589584 CAPLUS
DN 89:108584
TI Insecticidal 1-(substituted benzoyl)-3-(substituted pyrazinyl)ureas
IN Miesel, John Louis
PA Eli Lilly and Co., USA
SO U.S., 15 pp.
CODEN: USXXAM

DT Patent
LA English
FAM.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4083977	A	19780411	US 1976-742948	19761110
US 3984137	A	19761005	US 1975-595504	19750714
AT 7705635	A	19800615	AT 1977-5635	19770729
AT 360800	B	19810126		
PRAI US 1974-507492	A2	19740919		
US 1975-595504	A3	19750714		
AT 1975-7146	A	19750917		

L5 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1978:50924 CAPLUS
DN 88:50924
TI 1-Benzoyl-3-pyrazinylureas
PA Eli Lilly and Co., USA
SO Jpn. Kokai Tokkyo Koho, 24 pp.
CODEN: JKKXAF

DT Patent
LA Japanese
FAM.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 52010285	A2	19770126	JP 1976-1426	19760101
PRAI US 1975-895904	A	19750714		

L5 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1976:421468 CAPLUS
DN 85:21468
TI 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas
IN Miesel, John L.
PA Eli Lilly and Co., USA
SO Ger. Offen., 70 pp.
CODEN: GWXXBY
DT Patent
LA German

IN Miesel, John L.
PA Eli Lilly and Co., USA
SO U.S., 19 pp.
CODEN: USXXAM

DT Patent
LA English
FAM.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4160834	A	19790710	US 1977-861733	19771219
AT 7705635	A	19800615	AT 1977-5635	19770729
AT 360800	B	19810126		
PRAI US 1974-507492	A2	19740919		
US 1975-595904	A2	19750714		
US 1977-775813	A2	19770309		
AT 1975-7146	A	19750917		

L5 ANSWER 47 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1979:152238 CAPLUS
DN 90:152238
TI 1-(Meno-o-substituted benzoyl)-3-(substituted pyrazinyl)ureas
IN Miesel, John Louis; Abdulla, Riaz Fazal; Terando, Norman Henry
PA Eli Lilly and Co., USA
SO Ger. Offen., 86 pp.
CODEN: GWXXBY

DT Patent
LA German
FAM.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2926893	A1	19790118	DE 1978-2826893	19780619
US 4133956	A	19790109	US 1977-819639	19770727
IL 54928	A1	19800228	IL 1978-54928	19780615
IL 64263	A1	19800930	IL 1978-64263	19780615
FR 2398738	A1	19790223	FR 1978-18187	19780616
FR 2398738	B1	19810508		
IN 149912	A	19820529	IN 1978-CA666	19780616
BE 868228	A1	19781219	BE 1978-8936	19780619
GB 2001053	A	19790124	GB 1978-27260	19780619
GB 2001053	B2	19800526		
AU 516805	B2	19810604	AU 1978-37249	19780619
AU 7837249	A1	19800103		
GB 2066806	A	19810715	GB 1980-19107	19780619
GB 2066806	B2	19820818		
GB 2064566	A	19811015	AT 1978-4456	19780619
BE 367046	B	19800525		
CA 1129861	A1	19820817	CA 1978-305703	19780619
HU 23227	O	19820830	HU 1978-E1793	19780620
HU 180726	B	19830429		
RO 780649	P	19830803	RO 1978-94410	19780620
RU 29287	O	19840130	HU 1982-1470	19780620
HU 185336	B	19850128		
DK 7802793	A	19781223	DK 1978-2793	19780621
SE 7807127	A	19781223	SE 1978-7127	19780621
NL 7806678	A	19781229	NL 1978-6678	19780621
BR 7803939	A	19790220	BR 1978-3939	19780621
ZA 7803553	A	19800227	ZA 1978-3553	19780621
CS 198104	P	19800530	CS 1978-4095	19780621
CS 198105	P	19800530	CS 1978-8519	19780621
CS 198106	P	19800530	CS 1978-8520	19780621
SU 799462	D	19810123	SU 1978-2628947	19780621
CH 638500	A	19830930	CH 1978-6770	19780621
JP 54009288	A2	19790124	JP 1978-76343	19780622
ES 471057	A1	19800116	ES 1978-471057	19780622

FAM.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2541116	A1	19760408	DE 1975-2541116	19750915
DE 2541116	C2	19850718		
IN 142286	A	19770618	IN 1975-CA1744	19750910
BE 833208	A1	19760311	BE 1975-1006877	19750911
IL 48092	A1	19790312	IL 1975-48092	19750912
AU 7584845	A1	19770324	AU 1975-84845	19750915
GB 1521714	A	19780816	GB 1975-37933	19750916
CA 1070308	A1	19800122	CA 1975-235561	19750916
NL 7510901	A	19760323	NL 1975-10901	19750917
ZA 7505945	A	19770427	ZA 1975-5945	19750917
AT 7507146	A	19771015	AT 1975-7146	19750917
CS 195710	P	19800229	CS 1975-6298	19750917
DK 7504195	A	19760320	DK 1975-4195	19750918
SE 7510474	A	19760322	SE 1975-10474	19750918
SE 426066	B	19821206		
SE 426066	C	19830317		
PL 102954	P	19790531	PL 1975-197527	19750918
PL 106054	P	19791130	PL 1975-183470	19750918
CH 617192	A	19800514	CH 1975-12147	19750918
HU 19446	O	19810228	HU 1975-E1646	19750918
HU 177200	P	19810829		
JP 51056480	A2	19760518	JP 1975-114226	19750919
BR 7506073	A	19760803	BR 1975-6073	19750919
FR 2399327	A1	19760827	FR 1975-28772	19750919
FR 2399327	B1	19780407		
DD 123341	C	19761212	DD 1975-188451	19750919
ES 441124	A1	19770616	ES 1975-441124	19750919
DD 128762	C	19771207	DD 1975-196898	19750919
SU 662011	D	19790505	SU 1975-2171811	19750919
SU 660566	D	19790430	SU 1976-2380308	19760709
AT 7705635	A	19800615	AT 1977-5635	19770729
AT 360800	B	19810126		
SE 7806517	A	19780602	SE 1978-6517	19780602
SE 420042	B	19810914		
SE 420042	C	19820107		
PRAI US 1974-507492	A	19740919		
AT 1975-7146	A	19750917		

L5 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1973:537092 CAPLUS
DN 79:137092
TI Pteridines. XXIX. Unequivocal route to 2,4-diamino-6-substituted pteridines
AU Taylor, Edward C.; Perlman, Katherine L.; Kim, Young-Ho; Sword, Ian P.; Jacobi, Peter A.
CS Dep. Chem., Princeton Univ., Princeton, NJ, USA
SO Journal of the American Chemical Society (1973), 95(19), 6413-18
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA English

-- LOG HOLD
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
56.55 218.95
SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:44:37 ON 29 JUN 2005
Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPAI6232CT

PASSWORD:

***** RECONNECTED TO STN INTERNATIONAL *****
SESSION RESUMED IN FILE 'CAPLUS' AT 14:51:17 ON 29 JUN 2005
FILE 'CAPLUS' ENTERED AT 14:51:17 ON 29 JUN 2005
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS

FULL ESTIMATED COST

--> D HIS

(FILE 'HOME' ENTERED AT 14:42:20 ON 29 JUN 2005)

FILE 'REGISTRY' ENTERED AT 14:42:30 ON 29 JUN 2005

L1 STRUCTURE UPLOADED

L2 OUR L1

L3 50 S L2

L4 978 S L2 SSS FULL

FILE 'CAPLUS' ENTERED AT 14:44:08 ON 29 JUN 2005

L5 51 S L4

--> D L5 11, 12, 14, 18-51 IBIB ABS HITSTR

L5 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 2004:20338 CAPLUS

DOCUMENT NUMBER: 140:77031

TITLE: N-heteroaryl-N'-heterocyclureas as neuropeptide Y Y5

receptor antagonists

INVENTOR(S): Stamford, Andrew; Dong, Youhao; McCombie, Stuart W.;

Wu, Yusheng

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 84 pp., Cont.-in-part of U.S.

Ser. No. 26,451.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004006086	A1	20040108	US 2002-177345	20020620
US 2003055062	A1	20030320	US 2001-26651	20011218
PRIORITY APPLN. INFO.:			US 2000-257308P	F 200001221
			US 2001-26651	A2 20011218


OTHER SOURCE(S): MARPAT 140:77031

G1




RN 438584-83-9 CAPLUS

CN 4-Piperidinamine, 1-((5-(2,5-difluorophenyl)pyrazinyl)amino)carbonyl-N-methyl- (9CI) (CA INDEX NAME)




RN 438584-84-0 CAPLUS

CN 4-Piperidinamine, 1-((5-(2,5-difluorophenyl)pyrazinyl)amino)carbonyl-N-methyl- (9CI) (CA INDEX NAME)



RN 438584-86-4 CAPLUS

CN 4-Piperidinamine, N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 2003:395950 CAPLUS

DOCUMENT NUMBER: 139:395950


TITLE: Preparation of substituted pyrazines as protein kinase

modulators

INVENTOR(S): Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tsafai,

Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn,

ONLY PRIOR
ART HITS FROM L5
SELECTED -
THOSE
RECORDS
ARE
DISPLAYED
IBIB, ABS,
HIT STR...



11

AB R2NHCOCMeZIR1 [1; R = fluorophenyl, R1 = alkanyl, alkylsulfonyl,

pyridinyl(carbonyl), etc.; Z = pyridine-, pyrazine-, or
pyrimidine-2,5-diyl, etc.; Z1 = e.g., piperidine-4,1-diyl] were prepared
Thus, 3,5-P2C6H3B(OR)2 was condensed with 2-bromo-5-nitropyridine and the
reduced product condensed with COCl2 and N-methyl-1-(2-
pyridinyl)piperidine-4-amine to give 11. Data for biol. activity of 1
were given. Pharmaceutical composition comprising the compound 1 is claimed.

IT 438584-80-6F 438584-81-7F 438584-82-8F


438584-83-9F 438584-84-0F 438584-86-4F

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

[preparation of N-heteroaryl-N'-heterocyclureas as neuropeptide Y Y5
receptor antagonists]


RN 438584-80-6 CAPLUS

CN 4-Piperidinamine, 1-acetyl-N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 438584-81-7 CAPLUS

CN 4-Piperidinamine, N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 438584-82-8 CAPLUS

CN 4-Piperidinamine, N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko,
Larisa; Ahmad, Neel Kumar; Tsang, Tse H.; Huss, John
M.; Peto, Ceaba J.; Rice, Kenneth D.; Ibrahim, Mohamed
Abdulkader; Schnepf, Kevin Luke; Shi, Xian; Leahy,
James William; Chen, Jeff; Dalrymple, Lisa Esther;
Forreth, Timothy Patrick; Huynh, Tai Phat; Mann,
Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy

PATENT ASSIGNEE(S):

SOURCE: PCT Int. Appl., 468 pp.,

CODEN: PIXAD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093297	A2	20031113	WO 2003-US13869	20030502
WO 2003093297	A3	20040701		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
EW:	GM, GR, KE, LS, MW, MZ, SD, SL, SZ, TG, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GW, IL, IN, KE, NE, NG, SN, TD, TG			
CA 2484209	AA	20031113	CA 2003-2484209	20030502
EP 1501514	A2	20050202	EP 2003-728690	20030502
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			US 2002-377933P	P 20020503
			WO 2003-US13869	W 20030502

OTHER SOURCE(S): MARPAT 139:395950

G1



AB This invention relates to compds. I [R1 = H, halo, CN, etc.; R2, R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = N, CH; A = CO, CS, C(NR6), R7 (when A = R7, E does not exist); R6 = H, NO2, CN, etc.; R7 = (un)substituted 5-7 membered heterocyclyl, E = NR8R9, NR8R9, OR4, etc.; R8 = H, alkyl; R9 = H, heteroarylalkyl, etc.; NR8R9 = (un)substituted 5-7 membered heterocyclyl, W = 6-10 membered arylene, 5-10 membered heteroarylene, X = a bond, (un)substituted alkylene, O(CH2)2-30, etc.; Y = H, alkyl, aryl, etc.; with proviso] for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compds. containing such compds. Even more specifically, the invention relates to compds. I that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Preparation of representative compds. I is

described. Thus, amidation of 3-amino-6-phenylpyrazinecarboxylic acid (preparation given) with benzylamine afforded 67% 3-amino-6-phenyl-N-(phenylmethyl)pyrazine-2-carboxamide which showed IC50 of 10,000 nM or greater against Chk1. Table presenting activity data with respect to Chk1 for over 1000 compds. I is given. Methods of therapeutically or prophylactically using the compds. I and compds. to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amts. of such compds.


IT 625459-31-6P 625459-40-7F 625459-42-9P
625459-44-1P 625463-13-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of protein kinase modulators)


RN 625459-31-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(2-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 625459-40-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 625459-42-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 625459-44-1 CAPLUS


CA 2467870 AA 20030605 CA 2002-2467870 20021115
US 2003144297 A1 20040818 US 2002-298193 20021115
EP 1446387 A1 20040818 EP 2002-780507 20021115

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR

BR 2002014309 A 20041013 BR 2002-14309 20021115
US 2005049257 A1 20050303 US 2004-844004 20040512
US 2001-332052P P 20011121
US 2002-358546P P 20020221
US 2002-388285P P 20020613
US 2002-410378P P 20020913
US 2002-298193 A1 20021115
WO 2002-US33642 W 20021115

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 139.6891
OI



AB Substituted aryl 1,4-pyrazine derivs. (shown as I; variables defined below; e.g. 5-(2,4-dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-diethylpyrazine-2-amine) and their use in treating anxiety disorders, depression and stress related disorders are disclosed. The binding affinity of I for the corticotropin releasing factor type 1 receptor expressed as IC50 values generally ranges from approx. 0.5 nM to approx. 10 nM; no specific values are given. Although the methods of preparation are not claimed, 131 example preps. of I and 190 example preps. of intermediates are included. For I: X = -NR3R4, -OR3, -CR3R5R5, -C(O)R3, -S(O)NR3, -NR3C(O)R4, or -NR3S(O)NR4, n = 0-2; Ar = aryl, substituted aryl, heteroaryl, or substituted heteroaryl; R1, R2, and R5 = halogen, -NO2, -OR, -Ra, -ORa, -S(O)NRa, -NRaRa, -C(O)NRaRa, -C(S)NRaRa, -S(O)NRaRa, -NRaS(O)NRa, -NRaC(O)ORa, -OC(O)NRaRa, -NRaC(O)NRaRa, -NRaC(S)NRaRa, -C(O)ORa, -C(S)ORa, or -OC(O)ORa. R3 and R4 = Ra or substituted and/or unsubstituted heterocycloalkyl, heteroaryl, aryl, aryl cycloalkyl, heteroaryl cycloalkyl, aryl heterocycloalkyl, or heteroaryl heterocycloalkyl; Ra = H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl (unsubstituted with 1 to 5 of R1, -OR1, -S(O)NR1, NR1R1, oxo, thiono (S), Ph, heteroaryl, or heterocycloalkyl; R1 = H, halogen, -NO2, -NH2, -OR, -SR, -CN, -C(O)NH2, -C(O)NRalkyl, -C(O)NRalkylalkyl, -Oalkyl, NRalkyl, NRalkylalkyl, -S(O)NRalkyl, SO2NH2, SO2NRalkyl and SO2NRalkylalkyl, alkyl, cycloalkyl, haloalkyl, Ph, benzyl, heteroaryl, or heterocycloalkyl; addnl. details including specifically excluded compds. are given in the claims. Compds. I are also claimed effective for screening ligands for CRF1 receptors and for detecting CRF1 receptors in tissues.


IT 535936-71-1P, cis-5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-(4-propoxytetrahydrofuran-3-yl)pyrazine-2-amine
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug candidate and receptor detection and ligand screening agent; chromatog. resolution; preparation of substituted aryl pyrazine derivs. as

CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)

RN 535936-71-1 CAPLUS


CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-((1R,4R)-

CN Pyrazinecarboxamide, 3-amino-6-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 625463-13-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-((2-fluoro-5-((phenylmethyl)amino)carbonyl)phenyl)-N-methyl- (9CI) (CA INDEX NAME)



LS ANSWER 14 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:434540 CAPLUS

DOCUMENT NUMBER: 139:6891

TITLE: Preparation of substituted aryl pyrazine derivatives as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders

INVENTOR(S): Verhoest, Patrick R.; Hoffman, Robert L.; Corbett, Jeffrey W.; Ennis, Michael D.; Frank, Kristine E.; Pu, Jian-Min

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 271 pp.

CODEN: PIKMD2

PATENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045924	A1	20030605	WO 2002-US33642	20021115
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PA, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LG, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG			

tetrahydro-4-propoxy-3-furanyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 535936-73-3F, 5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-((1R,4R)-4-propoxytetrahydrofuran-3-yl)pyrazine-2-amine 535936-74-4F, 5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-((1S,4S)-4-propoxytetrahydrofuran-3-yl)pyrazine-2-amine

RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate and receptor detection and ligand screening agent; preparation of substituted aryl pyrazine derivs. as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)

RN 535936-73-3 CAPLUS

CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-((1R,4R)-tetrahydro-4-propoxy-3-furanyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535936-74-4 CAPLUS


CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-((1S,4S)-tetrahydro-4-propoxy-3-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 535934-78-2P, 5-(2,4-Dichlorophenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine 535935-16-1F, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine 535935-24-1F, cis-1-[(5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-1,2,3,4-tetrahydronaphthalen-2-ol 535935-76-3F, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(cis-2-ethyl-6-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine 535936-06-2F, Benzyl cis-3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-4-ethoxypyrrolidine-1-carboxylate 535936-07-3P, 5-(2,4-Dichlorophenyl)-N-(cis-4-ethoxypyrrolidin-3-yl)-3,6-diethylpyrazin-2-amine 535936-26-6F, Benzyl (3R,4S)-3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-4-ethoxypyrrolidine-1-carboxylate 535936-27-7F, 5-(2,4-Dichlorophenyl)-N-(1R,4S)-4-ethoxypyrrolidin-3-yl)-3,6-diethylpyrazin-2-amine 535936-29-9F, Benzyl (3R,4S)-3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate 535936-30-2P 535936-36-8P, Methyl (3R,4S)-3-[(3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl)amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate 535936-39-1F, Benzyl (3R,4S)-3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrolidine-1-carboxylate 535936-41-5F, Benzyl (3R,4S)-3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate 535936-42-6F, 5-(2-Chloro-4-methoxyphenyl)-N-((3R,4S)-4-ethoxypyrrolidin-3-yl)-3,6-diethylpyrazin-2-amine 535936-45-9F 535938-32-0F, Methyl 3-(2,4-dichlorophenyl)-6-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methoxypyrazine-2-carboxylate
 RL: ARG (Analytical reagent use); EUV (Biological use, unclassified); PAC (Pharmacological activity); ECT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate and receptor detection and ligand screening agent; preparation of substituted aryl pyrazine deriva. as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)

RN 535934-78-2 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 535935-16-1 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydro-6-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-07-3 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-ethoxy-, phenylmethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-26-6 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-ethoxy-, phenylmethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-27-7 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(3R,4S)-4-ethoxy-3-pyrrolidinyl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535935-24-1 CAPLUS
 CN 2-Naphthalenol, 1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-1,2,3,4-tetrahydro-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535935-76-3 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-ethyl-2,3-dihydro-6-methoxy-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 535936-06-2 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-ethoxy-, phenylmethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)


RN 535936-29-9 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, phenylmethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-30-2 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4S)-4-(2-fluoroethoxy)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-36-8 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[(3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl)amino]-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

diethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine
535935-06-95, 2-(2,4-Dichlorophenyl)-3,6-diethyl-5-(1,2,3,4-tetrahydronaphthalen-1-yl)oxypyrazine 535935-09-2F,
5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine 535935-10-5F,
5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine 535935-11-8F,
5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine 535935-20-7F,
5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]pyrazin-2-amine 535935-21-8F,
5-(2,4-Dichlorophenyl)-N-[(1R,2R)-2-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]-3,6-diethylpyrazin-2-amine 535935-25-2F,
5-(2,4-Dichlorophenyl)-N-(cis-1,3,4,5-tetrahydronaphthalen-1-yl)-3,6-diethylpyrazin-2-amine 535935-26-30, 5-(2,4-Dichlorophenyl)-N-(cis-2-ethoxy-1,2,3,4-tetrahydronaphthalen-1-yl)-3,6-diethylpyrazin-2-amine 535935-29-6F, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine 535935-32-1P,
5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(cis-5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine 535935-33-1P,
5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(Trans-5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine 535935-35-4F,
5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(Cis-5-ethyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine 535935-37-6F,
5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(Trans-5-ethyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine 535935-38-1P,
5-(2,4-Dichlorophenyl)-N-(3,4-dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine 535935-43-4F, 5-(2-Chloro-4-methylphenyl)-N-(3,4-dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine 535935-44-5P,
N-(3,4-Dihydro-2H-chromen-4-yl)-5-(2,4-dimethylphenyl)-3,6-diethylpyrazin-2-amine 535935-53-6F, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(Cis-5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine 535935-54-7F, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(Trans-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine 535935-58-1P,
5-(2,4-Dichlorophenyl)-N-(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl)-3,6-diethylpyrazin-2-amine 535935-59-2F, 5-(2,4-Dichlorophenyl)-N-(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-diethylpyrazin-2-amine 535935-60-6F, 5-(2,4-Dichlorophenyl)-N-(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl)-3,6-diethylpyrazin-2-amine 535935-64-9F, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(8-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine 535935-67-2F,
5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(6-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine 535935-79-6F, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine 535935-82-1E, N-[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine 535935-87-6P,
N-[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine 535935-93-4F, cis-N-[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]-6-ethyl-6-(2-hydroxy-5H-cyclopenta[b]pyridin-5-yl)pyrazin-2-amine 535935-94-5F,
N-(Cis-1,3,4,5-tetrahydronaphthalen-1-yl)-3,6-diethylpyrazin-2-amine 535935-00-6F, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-(trans-2-ethyl-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine 535936-08-4F, N-(cis-1-Acetyl-4-ethoxypyrrrolidin-3-yl)-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine 535936-09-5F,
N-(2,4-Dichlorophenyl)-N-(cis-1-ethoxy-4-ethoxypyrrrolidin-3-yl)-3,6-diethylpyrazin-2-amine 535936-10-8E, N-(cis-1-Ethoxy-4-ethoxy-2-methyl-4-chlorophenyl)-3,6-diethylpyrazin-2-yl)amino)-4-ethoxypyrrrolidine-1-carboxylate 535936-11-9F, 5-(2,4-Dichlorophenyl)-N-(cis-4-ethoxy-1-(methylfurfuryl)pyrrrolidin-3-yl)-3,6-diethylpyrazin-2-amine 535936-12-0F, Ethyl cis-3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-4-ethoxypyrrrolidine-1-carboxylate 535936-13-1F, N-[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-4-ethoxy-N,N-dimethylpyrrrolidine-1-carboxamide


[illegible]

535939-72-1F, N-[(1R,2S)-2-(2-Aminoethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-amine
535939-74-3F, N-[(1R,2S)-2-(2-Aminoethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine 535939-76-5P
- (1R,2S)-1-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-1-ylamine 535939-78-5P
- (1R,2S)-1-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-yl glycinate 535939-80-1F,
5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-methylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine
535939-82-3F, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-methylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine
535939-84-1F, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-dimethylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine
535939-86-7F, (1R,2S)-1-[(5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-yl N-methylglycinate
535939-88-9F, 5-(2-Chloro-4-methoxyphenyl)-N-[(1R,2S)-2-(2-dimethylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine
535939-90-1F, 5-(2-Chloro-4-methoxyphenyl)-N-[(1R,2S)-2-(2-dimethylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine
535939-92-5F, (1R,2S)-1-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-yl N,N-dimethylglycinate
535939-93-6F, (1R,2S)-1-[(5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-yl N,N-dimethylglycinate
535939-95-1F, 5-(2-Chloro-4-methoxyphenyl)-N-[(1R,2S)-2-(2-dimethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-yl methylcarbamate
535939-97-0F, 5-(4-Chloro-2-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine
535940-02-4F, (1R,2S)-1-[(5-(4-Chloro-2-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-yl acetate
535940-03-2F, 5-(4-Chloro-2-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine
535940-09-1F, (3R,4R)-4-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-yl acetate
535940-11-5F, (3R,4R)-4-[(5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-yl acetate
535940-13-1F, (3R,4R)-4-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-yl propionate
535940-15-9F, (3R,4R)-4-[(5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-yl propionate
535940-16-0F, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-[(3R,4R)-4-propionyltetrahydrofuran-3-yl]pyrazin-2-amine 535940-18-2P,
5-(2-Chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3R,4R)-4-(3-fluoropropoxy)tetrahydrofuran-3-yl]pyrazin-2-amine 535940-20-6F,
(3S,4R)-3-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-4-(2-fluoroethoxy)dihydrofuran-2(3H)-one 535940-22-0F,
(3S,4R)-3-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-4-ethoxydihydrofuran-2(3H)-one 535940-24-0F,
(3S,4R)-3-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-5-oxotetrahydrofuran-3-yl acetate 535940-26-2P,
(3R,4S)-4-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-5-oxotetrahydrofuran-3-yl propionate 535940-28-4P,
(3S,4R)-3-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-4-propionoxydihydrofuran-2(3H)-one 535940-30-0F,
(3S,4R)-3-[(5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]-4-(3-fluoropropoxy)tetrahydrofuran-2(3H)-one 535940-32-0F,
(1R,2S)-N-5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl-N'-ethyl-2,3-dihydro-1H-indene-1,2-diamine 535940-34-2F 535940-36-4P
- 5-(2,4-Dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-dimethoxypyrazin-2-amine 535940-38-6F, 3-Cyrclopropyl-5-(2,4-dichlorophenyl)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-dimethoxypyrazin-2-amine 535940-40-0F, 3-(2,4-Dichlorophenyl)-6-[[[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino]-5-ethylpyrazine-2-carboxamide 535940-42-2F, 3-(2,4-Dichlorophenyl)-6-[[[(1R,2S)-2-

ethoxy-2,3-dihydro-1H-inden-1-yl)amino]-5-methoxypyrazine-2-carboxamide
 535940-44-4P, 2-(2,4-Dichlorophenyl)-6-[[[(1R,2S)-2-ethoxy-2,3-
 dihydro-1H-inden-1-yl)amino]-5-(methylthio)pyrazine-2-carboxamide
 RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC
 (Pharmacological activity); SPN (Synthetic preparation); THO (Therapeutic
 use); ANST (Analytical study); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (drug candidate and receptor detection and ligand screening agent;
 preparation of substituted aryl pyrazine derivs. as CRF1 receptor
 antagonists useful against anxiety disorders, depression and stress
 related disorders)


RN 535934-30-6 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-
 inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 535934-31-7 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-methoxy-1H-
 inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-40-8 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1S,2S)-2,3-dihydro-2-methoxy-1H-
 inden-1-yl]-3,6-diethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-43-1 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2R)-2,3-dihydro-2-methoxy-1H-
 inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


RN 535934-32-8 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-(1-
 methylethoxy)-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-36-2 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1S,2R)-2,3-dihydro-2-methoxy-1H-
 inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 535934-39-5 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1S,2S)-2,3-dihydro-2-methoxy-1H-
 inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535934-44-2 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2R)-2,3-dihydro-2-methoxy-1H-
 inden-1-yl]-3,6-diethyl-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535934-45-3 CAPLUS
 CN Pyrazinamine, N-[(1R,2S)-2-(cyclopropylmethoxy)-2,3-dihydro-1H-inden-1-yl]-
 5-(2,4-dichlorophenyl)-3,6-diethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).






RN 535934-46-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2,3-dihydro-2-(2-propynyloxy)-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 535934-47-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2,3-dihydro-2-(2-methoxyethoxy)-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 535934-48-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2,3-dihydro-2-(2-propenyloxy)-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 535934-49-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-((1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 535934-50-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2,3-dihydro-2-propoxy-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 535934-51-1 CAPLUS
CN Ethanol, 2-(((1R,2S)-1-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)-2,3-dihydro-1H-inden-2-yl)oxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 535934-53-3 CAPLUS
CN Carbamic acid, dimethyl-, (1R,2S)-1-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 535934-54-4 CAPLUS
CN 1H-Inden-2-ol, 1-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)-2,3-dihydro-, acetate (ester), (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 535934-56-6 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 535934-57-7 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 535934-58-8 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, acetate (ester), (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 535934-60-2 CAPLUS
CN Pyrazinamine, N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-61-3 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-63-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-64-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-67-9 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(dimethylamino)phenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-66-0 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(dimethylanilino)phenyl)-3,6-diethyl-N-((1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 535934-71-5 CAPLUS
CN Pyrazinamine, 5-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 535934-74-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(2,3-dihydro-1H-inden-1-yl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 535934-75-9 CAPLUS
CN Pyrazinamine, N-(2,3-dihydro-1H-inden-1-yl)-5-(4-methoxy-2-methylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 535934-79-3 CAPLUS
CN Pyrazinamine, 5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 535934-83-9 CAPLUS
CN 1-Isoquinolinamine, N-[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 535934-87-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(3-ethyl-6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 535934-88-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(4,6-dimethyl-2-pyridinyl)-3,6-diethyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 535934-91-9 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydro-4-benzofuranyl)- (9CI) (CA INDEX NAME)




RN 535934-93-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydro-5-methyl-4-benzofuranyl)- (9CI) (CA INDEX NAME)




RN 535934-98-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5R)-5-ethyl-4,5,6,7-tetrahydro-4-benzofuranyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535934-99-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5S)-5-ethyl-4,5,6,7-tetrahydro-4-benzofuranyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 535935-02-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(3,4-dihydro-2H-1-benzothiopyran-4-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)




RN 535935-10-5 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2R)-1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 535935-13-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-ethoxy-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)


RN 535935-05-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 535935-06-9 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-diethyl-5-[(1,2,3,4-tetrahydro-1-naphthalenyl)oxy]- (9CI) (CA INDEX NAME)




RN 535935-09-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 535935-20-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-1,2,3,4-tetrahydro-2-methoxy-1-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535935-21-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2R)-2-ethoxy-1,2,3,4-tetrahydro-1-naphthalenyl]-3,6-diethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 535935-25-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-1,2,3,4-tetrahydro-2-methoxy-1-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535935-26-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-1,2,3,4-tetrahydro-1-naphthalenyl]-3,6-diethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535935-35-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5R)-5-ethyl-4,5,6,7-tetrahydrobenzo[b]thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535935-37-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5S)-5-ethyl-4,5,6,7-tetrahydrobenzo[b]thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535935-29-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4,5,6,7-tetrahydrobenzo[b]thien-4-yl)- (9CI) (CA INDEX NAME)



RN 535935-32-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5R)-4,5,6,7-tetrahydro-5-methylbenzo[b]thien-4-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 535935-33-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5S)-4,5,6,7-tetrahydro-5-methylbenzo[b]thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


RN 535935-42-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(3,4-dihydro-2H-1-benzopyran-4-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)



RN 535935-43-4 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methylphenyl)-N-(3,4-dihydro-2H-1-benzopyran-4-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)




RN 535935-44-5 CAPLUS
CN Pyrazinamine, N-(3,4-dihydro-2H-1-benzopyran-4-yl)-5-(2,4-dimethylphenyl)-3,6-diethyl- (9CI) (CA INDEX NAME)




RN 535935-53-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5R)-4,5,6,7-tetrahydro-5-propylbenzo[b]thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535935-54-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(4R,5S)-4,5,6,7-tetrahydro-5-propylbenzo[b]thien-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535935-58-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-methoxy-1H-inden-1-yl]-3,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535935-59-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535935-60-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-(1-methylethoxy)-1H-inden-1-yl]-3,6-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 535935-64-9 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydro-8-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 535935-67-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(2,3-dihydro-6-methoxy-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)




RN 535935-79-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(2,3-dihydro-5-methoxy-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)



RN 535935-82-1 CAPLUS
CN 5H-Cyclopenta[b]pyridin-7-amine, N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-6,7-dihydro- (9CI) (CA INDEX NAME)




RN 535935-07-4 CAPLUS
 CN 5H-Cyclopenta[b]pyridin-5-amine, N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-6,7-dihydro- (9CI) (CA INDEX NAME)




RN 535935-93-4 CAPLUS
 CN 5H-Cyclopenta[b]pyridin-7-amine, N-[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]-6-ethyl-6,7-dihydro-, (6R,7R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535935-99-0 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-ethyl-2,3-dihydro-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-00-6 CAPLUS
 CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-ethyl-2,3-dihydro-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-11-9 CAPLUS
 CN 3-Pyrrolidinamine, N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-4-ethoxy-1-(methylsulfonyl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-12-0 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, ethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-13-1 CAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-N,N-dimethyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-08-4 CAPLUS
 CN 3-Pyrrolidinamine, 1-acetyl-N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-4-ethoxy-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-09-5 CAPLUS
 CN 3-Pyrrolidinamine, N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-4-ethoxy-1-(1-oxopropyl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-10-8 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, methyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-14-2 CAPLUS
 CN 1-Pyrrolidinecarbothioamide, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-N,N-dimethyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-15-3 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, 1-methylethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-16-4 CAPLUS
 CN 1-Pyrrolidinecarbothioamide, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-N-methyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-17-5 CAPLUS
CN Morpholine, 4-[[[(3R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-1-pyrrolidinyl]carbonyl]]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-18-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, 2-fluoroethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-28-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-31-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-37-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[[5-(2-chloro-4-(dimethylamino)phenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-40-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, phenylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-44-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-46-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-51-7 CAPLUS
CN Pyrazinamine, N-[[[(3R,4S)-4-ethoxytetrahydro-3-furanyl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-57-3 CAPLUS
CN Pyrazinamine, N-[[[(3R,4R)-4-ethoxytetrahydro-3-furanyl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-67-5 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[[[(3R,4R)-tetrahydro-4-methoxy-3-furanyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-69-7 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[[[(3R,4R)-4-ethoxytetrahydro-3-furanyl]-3,6-diethyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 535936-76-6 CAPLUS


CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,4R)-4-(3-fluoropropoxy)tetrahydro-3-furanyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535936-84-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-propyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 535937-81-6 CAPLUS

CN Pyrazinamine, 3,6-dicyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535937-84-9 CAPLUS

CN Pyrazinamine, 6-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535937-87-2 CAPLUS

CN Pyrazinamine, 3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535937-90-7 CAPLUS

CN Pyrazinamine, 6-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535937-92-9 CAPLUS

CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-6-cyclopropyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535937-94-1 CAPLUS

CN Pyrazinamine, 6-cyclopropyl-5-(6-(dimethylamino)-4-methyl-3-pyridinyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535937-96-3 CAPLUS

CN Pyrazinamine, 3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535937-98-5 CAPLUS

CN Pyrazinamine, 3-cyclopropyl-5-[6-(diethylethylamino)-4-methyl-3-pyridinyl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535938-00-2 CAPLUS

CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3-cyclopropyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535938-01-3 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535938-03-5 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535938-08-0 CAPLUS

CN 1H-Indene-1,2-diamine, N1-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazinyl]-N2-ethyl-2,3-dihydro-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535938-10-4 CAPLUS

CN Acetamide, N-[(1R,2R)-1-[[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535938-12-6 CAPLUS

CN 1H-Indene-1,2-diamine, N1-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazinyl]-N2-(2-methoxyethyl)-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535938-14-0 CAPLUS


CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1S,2R)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-16-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1S,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-18-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-49-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-(acetyloxy)-4-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-, methyl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-51-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-(acetyloxy)-4-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-, methyl ester, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-53-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)




RN 535938-36-4 CAPLUS
CN Pyrazinacarboxylic acid, 6-[[[(1R,2S)-2-(acetyloxy)-2,3-dihydro-1H-inden-1-yl]amino]-3-(2,4-dichlorophenyl)-5-methoxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-47-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethenyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-55-7 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(2-fluoroethoxy)-, ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-59-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-propoxy-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-62-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(3-fluoropropoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-65-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-(3-fluoropropoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-66-2 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-propoxy-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-70-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-[(1-oxopropyl)amino]-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-73-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(1-oxopropyl)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-76-2 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-[(1-oxopropyl)amino]-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-79-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-[(1-oxopropyl)amino]-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-82-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(ethylamino)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-85-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(propylamino)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-87-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(3-fluoropropoxy)-, O-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-88-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, O-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-90-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-(3-fluoropropoxy)-, O-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-92-2 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-(3-fluoropropoxy)-, 2-pyridinylmethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-94-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 3-pyridinylmethyl ester, (3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-96-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 4-pyridinylmethyl ester, (3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-98-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 2-(1-piperidinyl)ethyl ester, (3R,4S)-(9CI) (CA INDEX NAME)



RN 535939-06-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(3-fluoropropoxy)-, 2-(1-pyrrolidinyl)ethyl ester, (3R,4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-07-2 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 2-(1H-imidazol-1-yl)ethyl ester, (3R,4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 535939-00-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 2-(4-morpholinyl)ethyl ester, (3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-02-7 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(1-oxopropoxy)-, 2-(4-morpholinyl)ethyl ester, (3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-03-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(3-fluoropropoxy)-, 2-(dimethylamino)ethyl ester, (3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-09-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 2-(methylamino)ethyl ester, (3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-11-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 2-aminoethyl ester, (3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-13-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-4-(2-fluoroethoxy)-, 2-hydroxyethyl ester, (3R,4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-15-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)-4-(2-fluoroethoxy)-, 2-methoxyethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-17-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)-4-ethoxy-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-18-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)-4-ethoxy-, 2-(2-oxo-1(2H)-pyridinyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-24-3 CAPLUS

CN 2-Pyrrolidinone, 4-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)-3-(2-fluoroethoxy)-1-(phenylmethyl)-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-26-5 CAPLUS

CN 2-Pyrrolidinone, 4-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)-3-(2-fluoroethoxy)-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-20-9 CAPLUS

CN 2-Pyrrolidinone, 3-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)-4-ethoxy-, (3S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-22-1 CAPLUS

CN 2-Pyrrolidinone, 3-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)-4-ethoxy-1-methyl-, (3S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-28-7 CAPLUS

CN 2-Pyrrolidinone, 4-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)-3-(2-fluoroethoxy)-1-methyl-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-30-1 CAPLUS


CN 2-Pyrrolidinone, 4-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)-3-(2-fluoroethoxy)-1-(phenylmethyl)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-32-3 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-ethyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 535939-34-5 CAPLUS

CN Furo[2,3-b]pyridine-2-carboxylic acid, 3-[[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl]amino]-2,3-dihydro-, ethyl ester, (2S,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-36-7 CAPLUS

CN Furo[2,3-b]pyridin-3-amine, N-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl]-2-(ethoxymethyl)-2,3-dihydro-, (2S,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-38-9 CAPLUS

CN Furo[2,3-b]pyridin-3-amine, N-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl]-2-ethyl-2,3-dihydro-, (2R,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

1-pyrrolidinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-45-8 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(2R)-2-(ethoxymethyl)-1-pyrrolidinyl]-3,6-diethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-47-0 CAPLUS


CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(2R)-2-(propoxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-49-2 CAPLUS


CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(2R)-2-[(2-fluoroethoxy)methyl]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 535939-40-3 CAPLUS

CN Furo[2,3-b]pyridin-3-amine, N-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazinyl]-2,3-dihydro-2-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-42-5 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-43-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-51-6 CAPLUS

CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(2R)-2-(ethoxymethyl)-1-pyrrolidinyl]-3,6-diethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-53-8 CAPLUS


CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-3,6-bis(methoxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535939-55-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-3,6-bis(methoxymethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535939-57-2 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-bis(methoxymethyl)pyrazinyl]amino]-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 535939-65-2 CAPLUS
CN Acetic acid, hydroxy-, (1R,2S)-1-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-67-4 CAPLUS
CN Acetic acid, hydroxy-, (1R,2S)-1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-59-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-bis(methoxymethyl)pyrazinyl]amino]-4-(2-fluoroethoxy)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-61-8 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-63-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)




RN 535939-68-5 CAPLUS
CN Acetic acid, methoxy-, (1R,2S)-1-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-70-9 CAPLUS
CN Acetic acid, methoxy-, (1R,2S)-1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-72-1 CAPLUS
CN Pyrazinamine, N-((1R,2S)-2-(2-aminoethoxy)-2,3-dihydro-1H-inden-1-yl)-5-(2-chloro-4-methoxyphenyl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-74-3 CAPLUS
CN Pyrazinamine, N-((1R,2S)-2-(2-aminoethoxy)-2,3-dihydro-1H-inden-1-yl)-5-(2,4-dichlorophenyl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-76-5 CAPLUS
CN Glycine, (1R,2S)-1-([5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino)-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-78-7 CAPLUS
CN Glycine, (1R,2S)-1-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-80-1 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-((1R,2S)-2,3-dihydro-2-(2-(methylamino)ethoxy)-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-82-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2,3-dihydro-2-(2-(methylamino)ethoxy)-1H-inden-1-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-84-5 CAPLUS
CN Glycine, N-methyl-, (1R,2S)-1-([5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino)-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-86-7 CAPLUS
CN Glycine, N-methyl-, (1R,2S)-1-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-88-9 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2-[2-(dimethylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-92-5 CAPLUS
CN Glycine, N,N-dimethyl-, (1R,2S)-1-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-93-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-[2-(dimethylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-95-8 CAPLUS
CN 1H-Inden-2-ol, 1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, methylcarbamate (ester), (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-95-8 CAPLUS
CN 1H-Inden-2-ol, 1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, methylcarbamate (ester), (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535939-97-0 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-02-4 CAPLUS
CN 1H-Inden-2-ol, 1-[(5-(4-chloro-2-methoxyphenyl)-3,6-diethylpyrazinyl)amino]-2,3-dihydro-, acetate (ester), (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-07-9 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-09-1 CAPLUS
CN 3-Puranol, 4-([5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino)tetrahydro-, acetate (ester), (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-11-5 CAPLUS
CN 3-Puranol, 4-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)tetrahydro-, acetate (ester), (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535940-13-7 CAPLUS
CN 3-Puranol, 4-([5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino)tetrahydro-, propanoate (ester), (3R,4R)- (9CI) (CA INDEX NAME)

RN 535940-20-6 CAPLUS
CN 2(3H)-Furanone, 3-([5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino)-4-(2-fluoroethoxy) dihydro-, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535940-22-8 CAPLUS
CN 2(3H)-Furanone, 3-([5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino)-4-ethoxydihydro-, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 535940-15-9 CAPLUS
CN 3-Puranol, 4-([5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino)tetrahydro-, propanoate (ester), (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-16-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4R)-tetrahydro-4-propoxy-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-18-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4R)-4-(3-fluoropropoxy)tetrahydro-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-24-0 CAPLUS
CN 2(3H)-Furanone, 4-(acetyloxy)-3-([5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino)dihydro-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-26-2 CAPLUS
CN 2(3H)-Furanone, 3-([5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino)dihydro-4-(1-oxopropoxy)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-20-4 CAPLUS
CN 2(3H)-Puranone, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]dihydro-4-propoxy-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-30-8 CAPLUS
CN 2(3H)-Puranone, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-(3-fluoropropoxy)dihydro-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-32-0 CAPLUS
CN 1H-Indene-1,2-diamine, N1-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-N2-ethyl-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-34-2 CAPLUS
CN Acetamide, N-[[1R,2S]-1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-36-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[[1R,2S]-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-38-6 CAPLUS
CN Pyrazinamine, 3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[[1R,2S]-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-40-0 CAPLUS
CN Pyrazinecarboxamide, 3-(2,4-dichlorophenyl)-6-[[1R,2S]-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino]-5-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-42-2 CAPLUS
CN Pyrazinecarboxamide, 3-(2,4-dichlorophenyl)-6-[[1R,2S]-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino]-5-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535940-44-4 CAPLUS

CN Pyrazinecarboxamide, 3-(2,4-dichlorophenyl)-6-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 535940-46-6P, 5-(2,4-Dichlorophenyl)-N-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-ethyl-3-(methylthio)pyrazin-2-amine
 535940-48-8P, 5-(2,4-Dichlorophenyl)-N-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-ethyl-3-methoxypyrazin-2-amine
 535940-50-2P, 5-(2,4-Dichlorophenyl)-N-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3-ethyl-6-methoxypyrazin-2-amine
 535940-52-4P, 5-(2,4-Dichlorophenyl)-N-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3-ethyl-6-(methylthio)pyrazin-2-amine
 535940-54-6P, 5-(2,4-Dichlorophenyl)-N-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-bis(methylthio)pyrazin-2-amine
 535940-56-8P, 6-(2,4-Dichlorophenyl)-3-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-ethylpyrazine-2-carboxamide
 535940-58-0P, 6-(2,4-Dichlorophenyl)-3-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methoxypyrazine-2-carboxamide
 535940-60-4P, 6-(2,4-Dichlorophenyl)-3-(((1R,2S)-2-ethoxy-2,3-


dihydro-1H-inden-1-yl)amino)-5-(methylthio)pyrazine-2-carboxamide
 535940-61-5F, 5-(2,4-Dichlorophenyl)-N-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-ethyl-N'-methylpyrazine-2,3-diamine
 535940-63-7F, 6-(2,4-Dichlorophenyl)-N-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-N',N''-dimethylpyrazine-2,3,5-triazine
 535940-65-9F, 3-(2,4-Dichlorophenyl)-N-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-5-ethyl-N'-methylpyrazine-2,6-diamine
 535940-71-7E, trans-N-[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine
 RL; ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); TEU (Therapeutic use); AMST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate and receptor detection and ligand screening agent; preparation of substituted aryl pyrazine deriva. as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)

RN 535940-46-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-ethyl-3-(methylthio)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535940-48-8 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-6-ethyl-3-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535940-50-2 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3-ethyl-6-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535940-52-4 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3-ethyl-6-(methylthio)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535940-54-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-bis(methylthio)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535940-56-8 CAPLUS


CN Pyrazinecarboxamide, 6-(2,4-dichlorophenyl)-3-(((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-56-0 CAPLUS
CN Pyrazinecarboxamide, 6-(2,4-dichlorophenyl)-3-[[[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-60-4 CAPLUS
CN Pyrazinecarboxamide, 6-(2,4-dichlorophenyl)-3-[[[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino]-5-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-61-5 CAPLUS
CN 2,3-Pyrazinediimine, 5-(2,4-dichlorophenyl)-N2-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-N3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-63-7 CAPLUS
CN Pyrazinetriamine, 6-(2,4-dichlorophenyl)-N2-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-N3,N5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535940-65-9 CAPLUS
CN 2,6-Pyrazinediimine, 3-(2,4-dichlorophenyl)-N2-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-5-ethyl-N6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535940-71-7 CAPLUS
CN SE-Cyclopenta[b]pyridin-7-amine, N-[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]-6-ethyl-6,7-dihydro-, (6R,7S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 535936-43-7, (3R,4S)-3-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-4-ethoxypyrrolidine-1-carboxylate
535936-34-2, Methyl 3-(2,4-dichlorophenyl)-6-[[[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-methoxypyrazine-2-carboxylate
RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of substituted aryl pyrazine derivs. as GPCR receptor antagonists useful against anxiety disorders, depression and stress related disorders)


RN 535936-43-7 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]-4-ethoxy-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535936-44-2 CAPLUS
CN Pyrazinecarboxylic acid, 3-(2,4-dichlorophenyl)-6-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-5-methoxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 535936-29-3P, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535936-35-1P, (1S,2R)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535936-37-3P, (1S,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl 4-nitrobenzoate 535936-38-6F, (1S,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535936-41-9F, (1R,2R)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-yl 4-nitrobenzoate 535936-42-0F, (1R,2R)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535936-52-2P, (1R,2S)-1-[[5-(2-Chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535936-59-9P, (1R,2S)-1-[[3,6-Diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535936-62-4F, (1R,2S)-1-[[5-(2,4-Dimethoxyphenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535936-65-7F, (1R,2S)-1-[[5-(2-Chloro-4-(dimethylamino)phenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535936-69-1P, (1R,2S)-1-[[5-(6-(Dimethylamino)-4-methylpyridin-3-yl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535935-19-4P, trans-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-1,2,3,4-tetrahydronaphthalen-2-ol 535935-57-0F, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol 535936-03-9F, Benzyl trans-3-[[5-(2,4-dichlorophenyl)-3,6-


diethylpyrazin-2-yl)amino]-4-hydroxypyrrrolidine-1-carboxylate
 535936-04-OP, Benzyl cis-3-[[5-(2,4-dichlorophenyl)-3,6-
 diethylpyrazin-2-yl)amino]-4-[[4-nitrobenzoyl]oxy]pyrrolidine-1-
 carboxylate 535936-05-1F, Benzyl cis-3-[[5-(2,4-dichlorophenyl)-
 3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrrolidine-1-carboxylate
 535936-25-5P, Benzyl (1R,4S)-3-[[5-(2,4-dichlorophenyl)-3,6-
 diethylpyrazin-2-yl)amino]-4-hydroxypyrrrolidine-1-carboxylate
 535936-49-3P, trans-4-[[3,6-Diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-
 yl)amino]tetrahydrofuran-3-yl 4-nitrobenzoate 535936-53-9P
 , cis-4-[[3,6-Diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-
 yl)amino]tetrahydrofuran-3-yl 4-nitrobenzoate 535936-55-1F,
 cis-4-[[3,6-Diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-
 yl)amino]tetrahydrofuran-3-yl 535936-65-3F, cis-4-[[5-(2-Chloro-
 4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-yl
 535937-53-2P, (1R,2S)-1-[[3,6-Dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol
 535937-55-4P, (1R,2S)-1-[[6-Cyclopropyl-5-(2,4-dichlorophenyl)-3-
 methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535937-58-7P
 , (1R,2S)-1-[[3-Cyclopropyl-5-(2,4-dichlorophenyl)-6-methylpyrazin-2-
 yl)amino]-2,3-dihydro-1H-inden-2-ol 535937-61-2P,
 (1R,2S)-1-[[6-Cyclopropyl-5-(2,4-dichlorophenyl)-3-ethylpyrazin-2-
 yl)amino]-2,3-dihydro-1H-inden-2-ol 535937-63-4F,
 (1R,2S)-1-[[5-(2-Chloro-4-methoxyphenyl)-6-cyclopropyl-3-ethylpyrazin-2-
 yl)amino]-2,3-dihydro-1H-inden-2-ol 535937-65-6F,
 (1R,2S)-1-[[6-Cyclopropyl-5-(6-(dimethylamino)-4-methylpyridin-3-yl)-3-
 ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535937-67-8F,
 (1R,2S)-1-[[3-Cyclopropyl-5-(2,4-dichlorophenyl)-6-ethylpyrazin-2-
 yl)amino]-2,3-dihydro-1H-inden-2-ol 535937-69-0F,
 (1R,2S)-1-[[3-Cyclopropyl-5-(6-(dimethylamino)-4-methylpyridin-3-yl)-6-
 ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535937-72-5F,
 (1R,2S)-1-[[5-(2-Chloro-4-methoxyphenyl)-3-cyclopropyl-6-ethylpyrazin-2-
 yl)amino]-2,3-dihydro-1H-inden-2-ol 535937-75-8F,
 (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-6-ethyl-3-methylpyrazin-2-yl)amino]-2,3-
 dihydro-1H-inden-2-ol 535937-78-1P, (1R,2S)-1-[[5-(2,4-
 Dichlorophenyl)-3-ethyl-6-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-
 ol 535938-04-6F, N-((1R,2R)-2-Azido-2,3-dihydro-1H-inden-1-yl)-
 3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-amine
 535938-06-8P, (1R,2R)-N-[[3,6-Dicyclopropyl-5-(2,4-
 dichlorophenyl)pyrazin-2-yl]-2,3-dihydro-1H-inden-1,2-diamine
 535938-26-2P, Methyl 3-(2,4-dichlorophenyl)-6-[[[(1R,2S)-2-hydroxy-
 2,3-dihydro-1H-inden-1-yl)amino]-5-methoxypyrazine-2-carboxylate
 535938-28-4P, Methyl 5-bromo-3-(2,4-dichlorophenyl)-6-[[[(1R,2S)-2-
 hydroxy-2,3-dihydro-1H-inden-1-yl)amino]pyrazine-2-carboxylate
 535938-30-8P, Ethyl 3-(2,4-dichlorophenyl)-6-[[[(1R,2S)-2-hydroxy-
 2,3-dihydro-1H-inden-1-yl)amino]-5-methoxypyrazine-2-carboxylate
 535938-42-2P, (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-6-methoxypyrazin-
 2-yl)amino]-2,3-dihydro-1H-inden-2-ol 535938-43-3F,
 (1R,2S)-1-[[3-Bromo-5-(2,4-dichlorophenyl)-6-methoxypyrazin-2-yl)amino]-
 2,3-dihydro-1H-inden-2-ol 535938-45-5F,
 (1R,2S)-1-[[5-(2,4-Dichlorophenyl)-6-methoxy-3-vinylpyrazin-2-yl)amino]-
 2,3-dihydro-1H-inden-2-ol
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of substituted aryl pyrazine derivs. as CRF1 receptor
 antagonists useful against anxiety disorders, depression and stress
 related disorders)
 RN 535934-29-3 CAPLUS
 CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-
 dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-35-1 CAPLUS
 CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-
 dihydro-, (1S,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-37-3 CAPLUS
 CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-
 dihydro-, 4-nitrobenzoate (ester), (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-38-4 CAPLUS
 CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-
 dihydro-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 535934-41-9 CAPLUS
 CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-
 dihydro-, 4-nitrobenzoate (ester), (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 535934-42-0 CAPLUS
 CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-
 dihydro-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 535934-52-2 CAPLUS


CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-((1R,2S)-2-[[[(1,1-
 dimethylsilyl]dimethylsilyl]oxy]ethoxy]-2,3-dihydro-1H-inden-1-yl)-3,6-
 diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-55-5 CAPLUS
 CN 1H-Inden-2-ol, 1-[[5-(2-chloro-4-methoxyphenyl)-3,6-
 diethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-59-9 CAPLUS
 CN 1H-Inden-2-ol, 1-[[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-62-4 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-[(2,4-dimethoxyphenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-65-7 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-[(2-chloro-4-(dimethylamino)phenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535934-69-1 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-[(6-(dimethylamino)-4-methyl-3-pyridinyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535935-19-4 CAPLUS
CN 2-Naphthalenol, 1-[[5-[(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-1,2,3,4-tetrahydro-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-05-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-[(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-hydroxy-, phenylmethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-28-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-[(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-hydroxy-, phenylmethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-49-3 CAPLUS
CN 3-Furanol, 4-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]tetrahydro-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535935-57-0 CAPLUS
CN 1H-Inden-2-ol, 1-[[5-[(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535936-03-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-[(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-hydroxy-, phenylmethyl ester, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-04-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-[(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]amino]-4-[(4-nitrobenzoyl)oxy]-, phenylmethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-53-9 CAPLUS
CN 3-Furanol, 4-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]tetrahydro-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-55-1 CAPLUS
CN 3-Furanol, 4-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]tetrahydro-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535936-65-3 CAPLUS
CN 3-Furanol, 4-[[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazinyl]amino]tetrahydro-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 535937-53-2 CAPLUS
CN 1H-Inden-2-ol, 1-([3,6-dicyclopentyl-5-(2,4-dichlorophenyl)pyrazinyl]amino)-2,3-dihydro-, (1R,2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-55-4 CAPLUS
CN 1H-Inden-2-ol, 1-([6-cyclopropyl-5-(2,4-dichlorophenyl)-3-methylpyrazinyl]amino)-2,3-dihydro-, (1R,2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-58-7 CAPLUS
CN 1H-Inden-2-ol, 1-([3-cyclopropyl-5-(2,4-dichlorophenyl)-4-methylpyrazinyl]amino)-2,3-dihydro-, (1R,2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-61-2 CAPLUS
CN 1H-Inden-2-ol, 1-([6-cyclopropyl-5-(2,4-dichlorophenyl)-3-ethylpyrazinyl]amino)-2,3-dihydro-, (1R,2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-63-4 CAPLUS
CN 1H-Inden-2-ol, 1-([5-(2-chloro-4-methoxyphenyl)-6-cyclopropyl-3-ethylpyrazinyl]amino)-2,3-dihydro-, (1R,2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-65-6 CAPLUS
CN 1H-Inden-2-ol, 1-([5-(2-chloro-4-methoxyphenyl)-6-(dimethylamino)-4-methyl-3-pyridinyl]-3-ethylpyrazinyl]amino)-2,3-dihydro-, (1R,2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-67-8 CAPLUS
CN 1H-Inden-2-ol, 1-([3-cyclopropyl-5-(2,4-dichlorophenyl)-4-methylpyrazinyl]amino)-2,3-dihydro-, (1R,2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-69-0 CAPLUS
CN 1H-Inden-2-ol, 1-([5-(2,4-dichlorophenyl)-6-cyclopropyl-3-ethylpyrazinyl]amino)-2,3-dihydro-, (1R,2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-72-5 CAPLUS
CN 1H-Inden-2-ol, 1-([5-(2-chloro-4-methoxyphenyl)-6-cyclopropyl-3-ethylpyrazinyl]amino)-2,3-dihydro-, (1R,2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-75-8 CAPLUS
CN 1H-Inden-2-ol, 1-([5-(2,4-dichlorophenyl)-6-ethyl-3-methylpyrazinyl]amino)-2,3-dihydro-, (1R,2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535937-78-1 CAPLUS
CN 1H-Inden-2-ol, 1-([5-(2,4-dichlorophenyl)-6-cyclopropyl-3-ethyl-6-methylpyrazinyl]amino)-2,3-dihydro-, (1R,2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-04-6 CAPLUS
CN Pyrazinamine, N-([(1R,2R)-2-azido-2,3-dihydro-1H-inden-1-yl]-3,6-dicyclopentyl-5-(2,4-dichlorophenyl))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-06-8 CAPLUS
CN 1H-Indene-1,2-diamine, N1-(3,6-dicyclopropyl)-5-(2,4-dichlorophenyl)pyrazinyl-2,3-dihydro-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-26-2 CAPLUS
CN Pyrazinecarboxylic acid, 3-(2,4-dichlorophenyl)-6-([(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-28-4 CAPLUS
CN Pyrazinecarboxylic acid, 5-bromo-3-(2,4-dichlorophenyl)-6-([(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino)-, methyl ester (9CI) (CA INDEX NAME)



RN 535938-45-5 CAPLUS
CN 1H-Inden-2-ol, 1-[(5-(2,4-dichlorophenyl)-3-ethenyl-6-methoxypyrazinyl]amino)-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:554265 CAPLUS
DOCUMENT NUMBER: 137:243205
TITLE: Comparison of the computer programs DEREK and TOPKAT to predict bacterial mutagenicity
AUTHOR(S): Carriello, Neal F.; Wilson, John D.; Britt, Ben H.; Wedd, David J.; Burlinson, Brian; Gombor, Vijay
CORPORATE SOURCE: Safety Assessment, GlaxoSmithKline Inc., Research Triangle Park, NC, 27709, USA
SOURCE: Mutagenesis (2002), 17(4), 321-329
CODEN: MUTAEX; ISSN: 0267-8357
PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English


AB The performance of two computer programs, DEREK and TOPKAT, was examined with regard to predicting the outcome of the Ames bacterial mutagenicity assay. The results of over 400 Ames tests conducted at Glaxo Wellcome (now GlaxoSmithKline) during the last 15 yr on a wide variety of chemical classes were compared with the mutagenicity predictions of both computer programs. DEREK was considered concordant with the Ames assay if (i) the Ames assay was neg. (not mutagenic) and no structural alerts for mutagenicity were identified or (ii) the Ames assay was pos. (mutagenic) and at least one structural alert was identified. Conversely, the DEREK output was considered discordant if (i) the Ames assay was neg. and any structural alert was identified or (ii) the Ames assay was pos. and no structural alert was identified. The overall concordance of the DEREK program with the Ames results was 65% and the overall discordance was 35%, based on over 400 compds. About 23% of the test mols. were outside the permissible limits of the optimum prediction space of TOPKAT. Another 4%

Absolute stereochemistry.




RN 535938-30-8 CAPLUS
CN Pyrazinecarboxylic acid, 3-(2,4-dichlorophenyl)-6-([(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino)-5-methoxy-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535938-42-2 CAPLUS
CN 1H-Inden-2-ol, 1-[(5-(2,4-dichlorophenyl)-6-methoxypyrazinyl]amino)-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 535938-43-3 CAPLUS
CN 1H-Inden-2-ol, 1-[(3-bromo-5-(2,4-dichlorophenyl)-6-methoxypyrazinyl]amino)-2,3-dihydro-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

of the compds. were either not processable or had indeterminate mutagenicity predictions; these mols. were excluded from the TOPKAT anal. If the TOPKAT probability was (i) 20.7 the mol. was predicted to be mutagenic, (ii) 50.3 the compound was predicted to be non-mutagenic and (iii) between 0.3 and 0.7 the prediction was considered indeterminate. From over 300 acceptable predictions, the overall TOPKAT concordance was 73% and the overall discordance was 27%. While the overall concordance of the TOPKAT program was higher than DEREK, TOPKAT fared more poorly than DEREK in the critical Ames-pos. category, where 60% of the compds. were incorrectly predicted by TOPKAT as neg. but were mutagenic in the Ames test. For DEREK, 54% of the Ames-pos. mols. had no structural alerts and were predicted to be non-mutagenic. Alternative methods of analyzing the output of the programs to increase the accuracy with Ames-pos. compds. are discussed.

IT 212778-82-0
RL: ADV (adverse effect, including toxicity); BIOL (Biological study) (computer programs DEREK and TOPKAT to predict bacterial mutagenicity)
RN 212778-82-0 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:487401 CAPLUS
DOCUMENT NUMBER: 137:47125
TITLE: N-heteroaryl-N'-heterocyclylureas as neuropeptide Y Y5 receptor antagonists
INVENTOR(S): Stanford, Andrew W.; Dong, Youhao; McCombie, Stuart W.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXDZ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049648	A1	20020627	WO 2001-0549302	20011217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, LC, LK, LE, LT, LU, LV, MA, MD, MG, MK, MN, MW, ME, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EW: GE, GM, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CP, CO, CI, CM, CA, GN, GD, GW, ML, MR, NE, SN, TD, TG				
CA 2432869	AA	20020627	CA 2001-2432869	20011217
AU 2002034956	A5	20020701	AU 2002-34056	20011217
EP 1343503	A1	20030917	EP 2001-985069	20011217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TH
 BR 2001016379 A 20020930 BR 2001-16379 20011217
 JP 2004516267 T2 20040603 JP 2002-550988 20011217
 NZ 526174 A 20041224 NZ 2001-526174 20011217
 ZA 2003004348 A 20040509 ZA 2003-4348 20030603
 BO 2003002861 A 20030821 BO 2003-2861 20030620
 PRIORITY APPL. INFO.: US 2000-257088 P 20001221
 WO 2001-0549302 W 20011217


OTHER SOURCE(S): MARPAT 137:47125
 AB R2NCOOCH2R1 ([1, R = fluorophenyl, R1 = alkanoyl, alkylsulfonyl, pyridinyl(carbonyl), etc.; Z = pyridine-, pyrazine-, or pyrrolidine-2,5-diyl, etc.; Z1 = e.g., piperidine-4,1-diyl) were prepared Thus, 3,5-PICHD(CI) was condensed with 2-bromo-5-nitropyridine and the reduced product condensed with COC12 and N-methyl-1-(2-pyridinyl)piperidine-4-amine to give I (R = C8H17-3,5, R1 = 2-pyridinyl, Z = pyridine-2,5-diyl, Z1 = piperidine-4,1-diyl). Data for biol. activity of I were given.
 IT 438584-80-6P 438584-81-7F 438584-82-8P
 438584-83-9P 438584-84-0F 438584-96-4P
 RL: PAC (Pharmacological activity), SYN (Synthetic preparation), THU (Therapeutic use), BIOL (Biological study), PREP (Preparation), USES (Uses)
 (n-heteroaryl-N'-heterocyclurases as neuropeptide Y Y5 receptor antagonists)
 RN 438584-80-6 CAPLUS
 CN 4-Piperidinamine, 1-acetyl-N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 438584-81-7 CAPLUS
 CN 4-Piperidinamine, N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 438584-82-8 CAPLUS
 CN 4-Piperidinamine, N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 438584-83-9 CAPLUS
 CN 4-Piperidinamine, 1-(cyclopentylcarbonyl)-N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 438584-84-0 CAPLUS
 CN 4-Piperidinamine, 1-(cyclopentylcarbonyl)-N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 438584-96-4 CAPLUS
 CN 4-Piperidinamine, N-[[[5-(2,5-difluorophenyl)pyrazinyl]amino]carbonyl]-N-methyl-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 20 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:183584 CAPLUS
 DOCUMENT NUMBER: 137:41243
 TITLE: N-O glucuronidation: a major human metabolic pathway in the elimination of two novel anti-convulsant drug

AUTHOR(S): candidates
 Temail, I. M.; Dear, G. J.; Roberts, A. D.; Plumb, R. S.; Ayrton, J.; Sweetman, B. C.; Bowers, G. D.
 CORPORATE SOURCE: Structural Identification Group, GlaxoSmithKline Research and Development, Ware, SG12 0DP, UK
 SOURCE: Xenobiotica (2002), 32(1), 29-43
 CODEN: XENOBH; ISSN: 0049-8254
 PUBLISHER: Taylor & Francis Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The urinary metabolites of the anti-convulsant compound 4-amino-1-(2,6-difluorophenyl)-1H-1,2,3-triazolo[4,5-c]-pyridine hydrochloride (G1265080) obtained following a single oral dose to man have been detected and quantified relative to each other using 19F-NMR spectroscopy. The human urinary metabolites of G1265080 were isolated using semipreparative HPLC and unequivocally characterized using 1H-NMR spectroscopy, two-dimensional heteronuclear NMR spectroscopy and mass spectrometry. The assignments of the N-(5)-oxide and the N-(5)-O-glucuronide metabolites of G1265080 were further confirmed by independent synthesis. The urinary metabolites obtained following single oral doses to dog and rat have also been isolated and characterized. The human urinary metabolites of G1265080 comprise the N-(5)-oxide, the quaternary N+-(5)-glucuronide, the 7-hydroxy glucuronide and a glucuronide conjugate of the N-(5)-oxide. The N-(5)-O-glucuronide conjugate is a novel species in human metabolism and is a significant route of elimination of G1265080 in man. The urinary metabolites of the potential anti-convulsant GW273293 (6-amino-3-(2,3,5-trichlorophenyl)pyrazin-2-ylamine) obtained following a single oral dose to man have also been isolated and characterized. The formation of a novel N-O-glucuronide was also observed and was shown to constitute a significant route of elimination of GW273293 in man.
 IT 212778-82-0, GW 273293 437651-94-0 437651-96-2
 437651-97-3 438553-55-0, GW 412646
 RL: PKT (Pharmacokinetics), BIOL (Biological study)
 (N-O glucuronidation, a major human metabolic pathway in elimination of two novel anti-convulsant drug candidates)
 RN 212778-82-0 CAPLUS
 CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 437651-94-0 CAPLUS
 CN Pyrazinium, 2,6-diamino-1-(β-D-glucopyranuronosyloxy)-3-(2,3,5-trichlorophenyl)-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 437651-96-2 CAPLUS
 CN 2(1H)-Pyrazinone, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 437651-97-3 CAPLUS
 CN β-D-Glucopyranosiduronic acid, 3,5-diamino-6-(2,3,5-trichlorophenyl)pyrazinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438553-55-0 CAPLUS
 CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)-, 1-oxide (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:10467 CAPLUS
 DOCUMENT NUMBER: 136:69823
 TITLE: Preparation of imidazole derivatives or salts thereof and drugs containing the derivatives or the salts
 INVENTOR(S): Kanno, Fujiko; Nagao, Yoshihiro; Isemae, Kazuo; Otsuka, Mari; Takahashi, Yoshiyuki; Ishii, Fumio; Hirota, Hiroyuki; Takeda, Sunao; Kawamoto, Noriyuki; Honda, Haruyoshi; Sato, Susumu
 PATENT ASSIGNEE(S): Sep Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000648	A1	20020103	WO 2001-JP4836	20010608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001064223	A5	20020108	AU 2001-64223	20010608
CA 2410391	AA	20021128	CA 2001-2410391	20010608
EP 1295880	A1	20030326	EP 2001-938563	20010608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002027896	A1	20031106	US 2002-258610	20021105
PRIORITY APPL. INFO.: JP 2000-194024 A 20000628			WO 2001-JP4836 W 20010608	


OTHER SOURCE(S): MARPAT 136:69823
 GI

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000199	A1	20020103	WO 2001-GB2923	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1294360	A1	20030326	EP 2001-943685	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004500984	T2	20040115	JP 2002-504980	20010629
US 2004045805	A1	20040311	US 2003-312434	20030606
PRIORITY APPL. INFO.: GB 2000-16040 A 20000629			WO 2001-GB2923 W 20010629	



AB The present invention relates to a novel process for preparing and harvesting crystalline particles, particularly pharmaceutical or carrier substances of a size suitable for inhalation therapy. Fluticasone propionate was dissolved in hot acetone and then allowed to cool to ambient temperature. A flow cell was then charged with a 4:1 mixture of water and acetone. Pump 1 (containing the fluticasone propionate in acetone) was set at a flow rate of 20 ml/min. Pump 2 (containing chilled water) was set at 80 ml/min. An ultrasound probe was set to deliver approx. 70-75 W of power. When the ultrasound probe and both pumps were turned on, rapid onset of crystallization occurred. The slurry output was collected in a flask and concentrated in vacuo until all of the acetone had been removed, leaving only aqueous slurry. The contents of the flask were then freeze dried overnight to give a free flowing fine dry white powder. No sieving or degradation of the particles by passing them through a screen was necessary.

IT 212778-82-0
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (process for preparing and harvesting crystalline pharmaceutical particles for inhalation therapy)
 RN 212778-82-0 CAPLUS
 CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 23 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN



AB Title compds. [1; R1, R2 each independently = aryl, heteroaryl; A, X1, X2 each independently = N, CH; Y, Z each independently = O, S, NH, SO2, CH2, NCH2, R3, R4, R5 each independently = H, alkyl, NH2, alkoxy, Cl; n = 1, 2, 3, 4; n = 0, 1, 2, 3, 4) and salts are prepared and formulation discussed. Title compds. 1 exhibit excellent inhibitory activities against the production of NO and IL-6 and are useful in the prevention or treatment of diseases resulting from over-development of NO and IL-6. Thus, the title compound II was prepared and tested as antiinflammatory in male ICR mouse with inhibition result at 30.5% for 3 mg/kg dosage.

IT 385413-98-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazole deriva. or salts thereof and drugs containing deriva. or salts)

RN 385413-98-9 CAPLUS
 CN Pyrazine, 2-(2,4-difluorophenyl)-5-[2-[4-(1H-imidazol-1-ylmethyl)phenoxy]ethoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:10260 CAPLUS
 DOCUMENT NUMBER: 136:74644
 TITLE: Novel process for preparing and harvesting crystalline pharmaceutical particles
 INVENTOR(S): Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 23 pp.
 CODEN: PIXXD2

ACCESSION NUMBER: 2002:10259 CAPLUS
 DOCUMENT NUMBER: 136:74643
 TITLE: Process for preparing and harvesting crystalline pharmaceutical particles
 INVENTOR(S): Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis
 PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
 SOURCE: PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000198	A1	20020103	WO 2001-GB2922	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1294359	A1	20030326	EP 2001-943684	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004500982	T2	20040115	JP 2002-504980	20010629
US 2003181432	A1	20030925	US 2003-312423	20030529
PRIORITY APPL. INFO.: GB 2000-15981 A 20000629			WO 2001-GB2922 W 20010629	

AB The present invention relates to a novel process for preparing and harvesting crystalline particles, particularly particles of pharmaceuticals or carrier substances of a size suitable for inhalation therapy. Thus, fluticasone propionate was dissolved in hot acetone and then allowed to cool to ambient temperature. A flow cell then charged with a 4:1 mixture of water and acetone. Pump 1 (containing the fluticasone propionate in acetone) was set at a flow rate of 20 ml/min. Pump 2 (containing water chilled to 3-5°) was set at a flow rate of 80 ml/min. The tip of a sono-probe was positioned above the inlet of Pump 1 and set to deliver 70-75 W of power. The resultant crystalline suspension was then collected and simultaneously filtered on a filter funnel fitted with GF/C glass microfiber filter. The damp filter cake was then washed with water and then resuspended in further demineralized water to prepare a 10% weight/weight slurry. The slurry was then rapidly frozen by immersing the flask containing the slurry in a solid carbon dioxide cooling bath containing acetone, to give an even coating of ice containing particles of fluticasone propionate. The mixture was then freeze dried in vacuo for 14-18 h to give a fine white powder containing particles of inhalable quality.

IT 212778-82-0
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (process for preparing and harvesting crystalline pharmaceutical particles)
 RN 212778-82-0 CAPLUS
 CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 24 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2001:859509 CAPLUS
 DOCUMENT NUMBER: 136:270314
 TITLE: Fluorescence properties of phenolate anions of coelenteramide analogues: the light-emitter structure in aequorin bioluminescence
 AUTHOR(S): Imai, Yuko; Shibata, Takuya; Maki, Shojiro; Niwa, Haruki; Chashi, Mamoru; Hirano, Takashi
 CORPORATE SOURCE: Department of Applied Physics and Chemistry, The University of Electro-Communications, Chofu, Tokyo, 182-8585, Japan
 SOURCE: Journal of Photochemistry and Photobiology, A: Chemistry (2001), 146(1-2), 95-107
 CODEN: JPPCEJ; ISSN: 1010-6030
 PUBLISHER: Elsevier Science S.A.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB To elucidate the ionic structure of the excited state of light-emitter coelenteramide in aequorin bioluminescence, the fluorescent properties of phenolate anions of coelenteramide analogs were investigated. Fluorescence of phenolate anion in non-polar solvents was observed by electronic excitation of a 1:1 hydrogen-bonded complex of a coelenteramide analog with a hydrogen-bond donor mol. such as n-butylamine. In polar solvents, the phenolate anion was directly generated using a base, and its fluorescence was studied. These results confirm that the singlet-excited state of phenolate anion of coelenteramide has an intramol. CT character, and that its fluorescence emission wavelength changes depending upon solvent polarity. The fluoro-substituent effect on the fluorescent property of phenolate anions was also clarified to help in explaining the bioluminescent property of fluorinated semi-synthetic aequorin. These results consistently support the assignment that the phenolate anion is the ionic structure of the excited light-emitter in BFP during AQ bioluminescence.


IT 404939-52-2P 404939-55-5P
 RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
 (fluorescence properties of phenolate anions of coelenteramide analogs and light-emitter structure in aequorin bioluminescence)
 RN 404939-52-2 CAPLUS
 CN Octanamide, N-[5-(2,3,5-trifluoro-4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl]- (9CI) (CA INDEX NAME)




RN 404939-55-5 CAPLUS
 CN Octanamide, N-[5-(2-fluoro-4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl]- (9CI) (CA INDEX NAME)



IT 404939-62-4 404939-66-8
 RL: PMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)
 (fluorescence properties of phenolate anions of coelenteramide analogs and light-emitter structure in aequorin bioluminescence in relation to)
 RN 404939-62-4 CAPLUS
 CN Octanamide, N-[5-(2,3,5-trifluoro-4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl]-, 1cm(1-) (9CI) (CA INDEX NAME)



RN 404939-66-8 CAPLUS
 CN Octanamide, N-[5-(2-fluoro-4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl]-, 1cm(1-) (9CI) (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 25 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2001:833264 CAPLUS
 DOCUMENT NUMBER: 135:257945
 TITLE: Two-step process for the preparation of 2,6-diamino-3-(2,3,5-trichlorophenyl)pyrazine
 INVENTOR(S): Ebney, Dean David; Kennedy, Andrew
 PATENT ASSIGNOR(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 11 pp.
 CODEN: PIKXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085674	A1	20011115	WO 2001-GB1929	20010502
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KO, KZ, MD, RU, TJ, TM, ZW, AM, AZ, BY, KO, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GW, ML, MR, NE, SN, TD, TO				
EP 1278721	A1	20030129	EP 2001-925711	20010502
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003532702	T2	20031105	JP 2001-582275	20010502
US 2003149053	A1	20030807	US 2002-275457	20021105
US 6803464	B2	20041012		

PRIORITY APPLN. INFO.: GB 2000-10971 A 20000505
 WO 2001-GB1929 W 20010502

OTHER SOURCE(S): CASREACT 135:257945
 AB A process for the preparation of 2-[[5-(2,3,5-trichlorophenyl)methyl]amino]acetamide or its acid-addition salts (e.g., the hydrobromide; I) comprises: (i) reaction of an acid salt of aminocetamide (e.g., aminocetamide dihydrobromide) with a source of cyanide (e.g., KCN); and (ii) reaction of the product of step (i) with 2,3,5-trichlorobenzaldehyde. 2,6-Diamino-3-(2,3,5-trichlorophenyl)pyrazine is prepared by the intramol. cyclodehydration reaction and oxidation of I or its acid-addition salts in the presence of a methanolic lithium hydroxide solution

IT 212778-62-0P
 RL: IMP (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (two-step process for the preparation of 2,6-diamino-3-(2,3,5-trichlorophenyl)pyrazine)
 RN 212778-62-0 CAPLUS
 CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 26 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2001:617986 CAPLUS
 DOCUMENT NUMBER: 135:180787
 TITLE: Preparation of substituted arylpyrazines and their binding with CRF1 receptors
 INVENTOR(S): Yoon, Taeyoung; Ge, Ping; Horvath, Raymond F.; De Lombaert, Stephane; Hodgetts, Kevin J.; Doller, Dario; Zhang, Cunyu
 PATENT ASSIGNOR(S): Neurogen Corporation, USA
 SOURCE: PCT Int. Appl., 193 pp.
 CODEN: PIKXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060806	A2	20010823	WO 2001-US264	20010216
WO 2001060806	A3	20020207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KO, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GW, ML, MR, NE, SN, TD, TO				
CA 2398937	AA	20010823	CA 2001-2398937	20010216
EP 1255740	A2	20021113	EP 2001-910939	20010216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003018035	A1	20030123	US 2001-788315	20010216
EE 200200453	A	20031215	EE 2002-453	20010216
JP 2004500383	T2	20040108	JP 2001-560191	20010216
BR 2001008633	A	20040210	BR 2001-8363	20010216
EP 1500653	A1	20050126	EP 2004-25531	20010216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 530404	A	20050324	NZ 2001-520484	20010216
BG 106968	A	20050430	BG 2002-106968	20020731
ZA 2002096103	A	20030820	ZA 2002-6103	20020731
NO 200203869	A	20020911	NO 2002-3869	20020815
PRIORITY APPLN. INFO.: US 2000-182934P P 20000216 US 2000-206455P P 20000522 EP 2001-910939 A3 20010216 WO 2001-US264 W 20010216				

OTHER SOURCE(S): MARPAT 135:180787
 GI



AB Arylpyrazine compds. I [Ar = substituted Ph, naphthyl, heterocyclyl; R1, R2 = H, halo, cyano, NO2, etc.; R3 = halo, amino, alkyl, etc.], including arylpyrazines that can bind with high affinity and high selectivity to


102(a)

CRP1 receptors, including human CRP1 receptors, were prepared E.g., N-(1-ethylpropyl)-5-(2,4-dimethoxyphenyl)-3,6-dimethylpyrazine-2-amine was prepared by reaction of 2-chloro-3,6-dimethylpyrazine with 1-ethylpropylamine, followed by bromination and reaction with 2,4-dimethoxybenzenboronic acid.

IT 355834-56-9P 355835-13-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of substituted arylpyrazines and their binding with CRP1 receptors)


RN 355834-56-9 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-3,6-dimethyl-5-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 355835-13-1 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




IT 355834-36-5P 355834-37-6P 355834-38-7P
 355834-40-1P 355834-41-2P 355834-44-5P
 355834-45-6P 355834-46-7P 355834-48-9P
 355834-49-0P 355834-50-3P 355834-52-5P
 355834-53-6P 355834-54-7P 355834-57-0P
 355834-58-1P 355834-59-2P 355834-60-5P
 355834-61-6P 355834-62-7P 355834-63-8P
 355834-64-9P 355834-65-0P 355834-66-1P
 355834-67-2P 355834-68-3P 355834-69-4P
 355834-70-7P 355834-71-8P 355834-72-9P
 355834-73-0P 355834-74-1P 355834-75-2P
 355834-76-3P 355834-77-4P 355834-78-5P
 355834-79-6P 355834-84-3P 355834-85-4P
 355834-86-5P 355834-87-6P 355834-88-7P
 355834-89-8P 355834-90-1P 355834-91-2P
 355834-92-3P 355834-93-4P 355834-94-5P
 355834-95-6P 355834-96-7P 355834-97-8P
 355834-98-9P 355834-99-0P 355835-00-6P
 355835-01-7P 355835-02-8P 355835-03-9P
 355835-04-0P 355835-05-1P 355835-06-2P




RN 355834-37-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-38-7 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-5-(4-methoxy-2-methylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-40-1 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-(methoxymethyl)propyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-41-2 CAPLUS


CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-(1-(methoxymethyl)propyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)

355835-07-3P 355835-08-4P 355835-09-5P
 355835-10-6P 355835-11-7P 355835-12-0P
 355835-14-2P 355835-15-3P 355835-16-4P
 355835-17-5P 355835-18-6P 355835-19-7P
 355835-20-0P 355835-21-1P 355835-22-2P
 355835-23-3P 355835-24-4P 355835-25-5P
 355835-26-6P 355835-27-7P 355835-30-2P
 355835-31-3P 355835-33-5P 355835-35-7P
 355835-37-9P 355835-38-0P 355835-39-1P
 355835-40-4P 355835-41-5P 355835-42-6P
 355835-43-7P 355835-44-8P 355835-45-9P
 355835-46-0P 355835-47-1P 355835-48-2P
 355835-49-3P 355835-50-6P 355835-51-7P
 355835-52-8P 355835-53-9P 355835-54-0P
 355835-55-1P 355835-56-2P 355835-57-3P
 355835-58-4P 355835-59-5P 355835-60-8P
 355835-61-9P 355835-62-0P 355835-63-1P
 355835-64-2P 355835-66-4P 355835-70-0P
 355835-71-1P 355835-72-2P 355835-73-3P
 355835-74-4P 355835-75-5P 355835-76-6P
 355835-77-7P 355835-78-8P 355835-79-9P
 355835-80-2P 355835-81-3P 355835-82-4P
 355835-83-5P 355835-84-6P 355835-85-7P
 355835-86-8P 355835-87-9P 355835-88-0P
 355835-89-1P 355835-90-4P 355835-91-5P
 355835-92-6P 355835-93-7P 355835-94-8P
 355835-95-9P 355835-96-0P 355835-97-1P
 355835-98-2P 355835-99-3P 355836-00-9P
 355836-02-1P 355836-03-2P 355836-04-3P
 355836-39-4P 355836-41-8P 355836-42-9P
 355836-46-3P 355836-47-4P 355836-48-5P
 355836-50-9P 355836-52-1P 355836-54-3P
 355836-56-5P 355836-57-6P 355836-58-7P
 355836-59-8P 355836-60-1P 355836-61-2P
 355836-62-3P 355836-63-4P 355836-64-5P
 355836-65-6P 355836-66-7P 355836-67-8P
 355836-68-9P 355836-69-0P 355836-70-3P
 355836-71-4P 355836-72-5P 355836-73-6P
 355836-74-7P 355836-75-8P 355836-76-9P
 355836-77-0P 355836-78-1P 355836-80-5P
 355836-81-6P 355836-82-7P 355836-83-8P
 355836-84-9P 355836-85-0P 355836-86-1P
 355836-87-2P 355836-88-3P 355836-89-4P
 355836-90-7P 355836-91-8P 355836-92-9P
 355836-93-0P 355836-94-1P 355836-95-2P
 355836-96-3P 355836-97-4P 355836-98-5P
 355836-99-6P 355837-00-2P 355837-01-3P
 355837-03-5P 355837-04-6P 355837-06-8P
 355837-07-9P 355837-08-0P 355837-09-1P
 355837-10-4P 355837-12-6P 355837-14-8P
 355837-23-9P 355837-24-0P 355837-25-1P
 355839-94-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted arylpyrazines and their binding with CRP1 receptors)


RN 355834-36-5 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-44-5 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-45-6 CAPLUS

CN Pyrazinamine, 5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-46-7 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-48-9 CAPLUS


CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-49-0 CAPLUS
CN Pyrazinamine, 5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-50-3 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methylphenyl)-3,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-52-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-53-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-60-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-61-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 355834-62-7 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-63-8 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)




RN 355834-54-7 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-57-0 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methyl-5-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 355834-58-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-59-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)




RN 355834-64-9 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-65-0 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 355834-66-1 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(4-methoxy-2-methylphenyl)-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-67-2 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)




RN 355834-68-3 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(4-methoxy-2-methylphenyl)-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-72-9 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 355834-69-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-73-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 355834-70-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-methoxymethylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-74-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(2-methyl-1-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-71-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-75-2 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(dimethylamino)phenyl)-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-76-3 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(dimethylamino)phenyl)-3,6-diethyl-N-(1-methoxymethylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-84-3 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-5-(2-methoxy-4,6-dimethylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-77-4 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(dimethylamino)phenyl)-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-85-4 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(2-methyl-1-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-78-5 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(dimethylamino)phenyl)-3,6-diethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-86-5 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(2-methyl-1-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-79-6 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(dimethylamino)phenyl)-3,6-diethyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 355834-87-6 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-88-7 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(1-methoxymethylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-89-8 CAPLUS
CN Pyrazine, 2-(1-ethylpropoxy)-5-(2-methoxy-4,6-dimethylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-90-1 CAPLUS
CN Pyrazine, 2-(cyclopropylmethoxy)-5-(2-methoxy-4,6-dimethylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-95-6 CAPLUS
CN Pyrazine, 2-(cyclopropylphenylmethoxy)-5-(2,4-dichlorophenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-96-7 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-[(2-propylcyclohexyl)oxy]- (9CI) (CA INDEX NAME)




RN 355834-97-8 CAPLUS
CN Pyrazine, 2-(2,4-dimethoxyphenyl)-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




RN 355834-98-9 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-91-2 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-5-(di-cyclopropylmethoxy)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-92-3 CAPLUS
CN Pyrazine, 2-(1-cyclohexylpropoxy)-5-(2,4-dichlorophenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-93-4 CAPLUS
CN Pyrazine, 2-(1-cyclopentylpropoxy)-5-(2,4-dichlorophenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-94-5 CAPLUS
CN Pyrazine, 2-(1-cyclopentylbutoxy)-5-(2,4-dichlorophenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-99-0 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355835-00-6 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N-(1-methoxymethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355835-01-7 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N-(1-methoxymethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355835-02-0 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-(2-(4-morpholinyl)ethoxy)phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-03-9 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-(2-(4-morpholinyl)ethoxy)phenyl]-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355835-04-0 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-(2-(4-morpholinyl)ethoxy)phenyl]-3,6-diethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 355835-08-4 CAPLUS
CN Pyrazinamine, N-(cyclopropylmethyl)-5-[2,4-dimethyl-6-(2-(4-morpholinyl)ethoxy)phenyl]-3,6-diethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 355835-09-5 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-(2-(4-morpholinyl)ethoxy)phenyl]-N,3,6-triethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 355835-10-8 CAPLUS
CN Pyrazinamine, 3-bromo-6-chloro-5-[2,4-dimethyl-6-(2-(4-morpholinyl)ethoxy)phenyl]-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-05-1 CAPLUS
CN Pyrazinamine, N-butyl-5-[2,4-dimethyl-6-(2-(4-morpholinyl)ethoxy)phenyl]-N,3,6-triethyl- (9CI) (CA INDEX NAME)




RN 355835-06-2 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-(2-(4-morpholinyl)ethoxy)phenyl]-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-07-3 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-(2-(4-morpholinyl)ethoxy)phenyl]-3,6-diethyl-N-(1-methoxymethyl)propyl- (9CI) (CA INDEX NAME)




RN 355835-11-9 CAPLUS
CN Pyrazinamine, 6-chloro-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 355835-12-0 CAPLUS
CN Pyrazinamine, 6-chloro-5-(2,4-dichlorophenyl)-3-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-14-2 CAPLUS
CN Pyrazinamine, 3-bromo-6-chloro-5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-15-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-fluoro- (9CI) (CA INDEX NAME)




RN 355035-14-4 CAPLUS
CN Pyrazinamine, 3-chloro-5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355035-17-5 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-iodo- (9CI) (CA INDEX NAME)




RN 355035-18-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355035-19-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethyl-N-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 355035-24-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355035-25-5 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-3-methoxy-5-(4-methoxy-2-methylphenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 355035-26-6 CAPLUS
CN Pyrazine, 2-ethyl-3-(1-ethylpropoxy)-5-methoxy-6-(2-methoxy-4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)




RN 355035-27-7 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-(trifluoromethoxy)phenyl)-6-(methylthio)- (9CI) (CA INDEX NAME)




RN 355035-20-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 355035-21-1 CAPLUS
CN Pyrazinamine, 3-bromo-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355035-22-2 CAPLUS
CN Pyrazinamine, 6-chloro-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355035-23-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355035-30-2 CAPLUS
CN 1-Butanol, 2-([5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]amino)- (9CI) (CA INDEX NAME)




RN 355035-31-3 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)




RN 355035-33-5 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 355035-35-7 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 355835-37-9 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 355835-38-0 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-39-1 CAPLUS
CN 2(1H)-Pyridinone, 5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 355835-40-4 CAPLUS
CN 2(1H)-Pyridinone, 3-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 355835-45-9 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 355835-46-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 355835-47-1 CAPLUS
CN Pyrazinamine, N-(cyclopropylmethyl)-5-(2,4-dichlorophenyl)-3,6-diethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 355835-48-2 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxy-5-pyrimidinyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-41-5 CAPLUS
CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(2-methoxy-1-(methoxymethyl)ethyl)- (9CI) (CA INDEX NAME)




RN 355835-42-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(2-methoxy-1-(methoxymethyl)ethyl)- (9CI) (CA INDEX NAME)




RN 355835-43-7 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(2-methoxy-1-(methoxymethyl)ethyl)- (9CI) (CA INDEX NAME)




RN 355835-44-8 CAPLUS
CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-(2-methoxy-1-(methoxymethyl)ethyl)- (9CI) (CA INDEX NAME)




RN 355835-49-3 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methoxy-4,6-bis(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 355835-50-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(dicyclopropylmethyl)-3,6-diethyl- (9CI) (CA INDEX NAME)




RN 355835-51-7 CAPLUS
CN 1,2-Propanediamine, N2-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-N1,N1-dimethyl- (9CI) (CA INDEX NAME)




RN 355835-52-8 CAPLUS
CN Pyrazinamine, N-(dicyclopropylmethyl)-5-(2,4-dimethoxyphenyl)-3,6-diethyl- (9CI) (CA INDEX NAME)




RN 355035-53-9 CAPLUS
CN Pyrazinamine, 5-[(2,6-dimethoxy-3-pyridinyl)-3,6-diethyl-N-(1-ethylpropyl)]- (9CI) (CA INDEX NAME)




RN 355035-54-0 CAPLUS
CN Pyrazinamine, N-(dicyclopropylmethyl)-5-(2,6-dimethoxy-3-pyridinyl)-3,6-diethyl- (9CI) (CA INDEX NAME)




RN 355035-55-1 CAPLUS
CN 1,2-Ethanediamine, N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-N',N'-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 355035-56-2 CAPLUS
CN Pyrazinamine, 5-(2,4-diethoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355035-61-9 CAPLUS
CN Phenol, 4-[(3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl)-3-methoxy]- (9CI) (CA INDEX NAME)




RN 355035-62-0 CAPLUS
CN Pyrazinamine, 5-(4-ethoxy-2-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355035-63-1 CAPLUS
CN Pyrazinamine, 3-(4-ethoxy-2-methoxyphenyl)-5-[2-methoxy-4-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355035-64-2 CAPLUS
CN Pyrazinamine, 5-(2,4-bis(1-methylethoxy)phenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355035-57-3 CAPLUS
CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 355035-58-4 CAPLUS
CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-ethoxy- (9CI) (CA INDEX NAME)




RN 355035-59-5 CAPLUS
CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 355035-60-8 CAPLUS
CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-(difluoromethoxy)- (9CI) (CA INDEX NAME)




RN 355035-66-4 CAPLUS
CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 355035-70-0 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355035-71-1 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-diethyl-5-[2-methoxy-1-(methoxymethyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 355035-72-2 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-diethyl-5-[2-methoxy-1-(methoxymethyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 355035-73-3 CAPLUS
CN Pyrazine, 2-(2,5-diethyl-3-(1-ethylpropoxy)-6-(2-methoxy-4-(trifluoromethoxy)phenyl))-3,6-dimethyl-5-((1-methyl-4-piperidinyl)oxy)- (9CI) (CA INDEX NAME)




RN 355035-74-4 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-((1-methyl-4-piperidinyl)oxy)- (9CI) (CA INDEX NAME)




RN 355035-75-5 CAPLUS
CN Pyrazine, 2-(1-cyclohexylbutoxy)-5-(2,4-dichlorophenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355035-76-6 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-5-((4-methoxycyclohexyl)oxy)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355035-77-7 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-((1-methyl-4-piperidinyl)oxy)- (9CI) (CA INDEX NAME)




RN 355035-78-8 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-((1-methyl-4-piperidinyl)oxy)- (9CI) (CA INDEX NAME)



RN 355035-79-9 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-((1-methyl-4-piperidinyl)oxy)- (9CI) (CA INDEX NAME)




RN 355035-80-2 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-5-((1-ethyl-3-piperidinyl)oxy)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355035-81-3 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-((1-ethyl-3-piperidinyl)oxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 355035-82-4 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-((1-ethyl-3-piperidinyl)oxy)- (9CI) (CA INDEX NAME)




RN 355035-83-5 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-((1-ethyl-3-piperidinyl)oxy)- (9CI) (CA INDEX NAME)




RN 355035-84-6 CAPLUS


CN 1-Butanamine, 2-[[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]oxy]- (9CI)




RN 355035-85-7 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-((1-ethyl-3-piperidinyl)oxy)- (9CI) (CA INDEX NAME)




RN 355035-86-8 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-5-((1-ethyl-3-pyrrolidinyl)oxy)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355035-87-9 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-((1-ethyl-3-pyrrolidinyl)oxy)- (9CI) (CA INDEX NAME)




RN 355035-00-0 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-(3-pyrrolidinyl)oxy- (9CI)
(CA INDEX NAME)




RN 355035-09-1 CAPLUS
CN Butanoic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 355035-90-4 CAPLUS
CN Pentanoic acid, 3-[[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 355035-95-9 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-diethyl-5-(1-ethylpropoxy)- (9CI)
(CA INDEX NAME)




RN 355035-96-0 CAPLUS
CN Morpholine, 4-[2-[2-[3,6-diethyl-5-(1-ethylpropoxy)pyrazinyl]-3,5-dimethylphenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 355035-97-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethoxy-6-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355035-98-2 CAPLUS




RN 355035-91-5 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-dimethyl-5-(4-pyridinyl)oxy- (9CI)
(CA INDEX NAME)



RN 355035-92-6 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(1-ethylpropoxy)-6-(2-methoxy-4,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 355035-93-7 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-5-(1-ethylpropoxy)-3,6-dimethyl- (9CI)
(CA INDEX NAME)




RN 355035-94-8 CAPLUS
CN Phenol, 2-[3,6-diethyl-5-(1-ethylpropoxy)pyrazinyl]-3,5-dimethyl- (9CI)
(CA INDEX NAME)


CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 355035-99-3 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355036-00-9 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355036-02-1 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[2-methoxy-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 355036-03-2 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355036-04-3 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-3,6-dimethyl-5-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 355036-39-4 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355036-41-8 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355036-42-9 CAPLUS
CN Pyrazinamine, 5-(3-chloro-4-(trifluoromethyl)phenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355036-52-1 CAPLUS
CN Pyrazine, 2,5-diethyl-3-[2-methyl-1-(1-methylethyl)propoxy]-6-[2-methyl-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355036-54-3 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 355036-56-5 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[2-methyl-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355036-57-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355036-46-3 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355036-47-4 CAPLUS
CN Pyrazinamine, 5-(2,6-dichloro-4-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355036-48-5 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(3-methyl[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)




RN 355036-50-9 CAPLUS
CN Pyrazine, 2-(2,4-dichlorophenyl)-3,6-diethyl-5-(1-methylbutoxy)- (9CI) (CA INDEX NAME)




RN 355036-58-7 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-ethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355036-59-8 CAPLUS
CN Carbonodithioic acid, O-[3-chloro-4-[5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazinyl]phenyl] S-propyl ester (9CI) (CA INDEX NAME)




RN 355036-60-1 CAPLUS
CN Pyrazine, 2,5-diethyl-3-[1-ethylpropoxy]-6-[2-methoxy-4,6-bis(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 355036-61-2 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(4-fluoro-2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 355836-62-3 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methylphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355836-63-4 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355836-64-5 CAPLUS
CN Carbonodithioic acid, O-[3-chloro-4-(3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl)phenyl] S-propyl ester (9CI) (CA INDEX NAME)




RN 355836-65-6 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2,6-dimethoxyphenyl)-3-ethoxy-N-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-70-3 CAPLUS
CN Pyrazine, 2-(2-chloro-4-methoxyphenyl)-3,6-diethyl-5-(2-methyl-1-(1-methylethyl)propoxy)- (9CI) (CA INDEX NAME)




RN 355836-71-4 CAPLUS
CN Benzenemethanol, 4-(3-ethyl-5-[(1-ethylpropyl)amino]-6-methoxypyrazinyl)-3,5-dimethoxy-α,α-dimethyl- (9CI) (CA INDEX NAME)




RN 355836-72-5 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-ethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-73-6 CAPLUS
CN Pyrazinamine, 3-ethyl-5-(2-ethyl-4-methoxyphenyl)-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-66-7 CAPLUS
CN Pyrazine, 2-(2,4-dimethoxyphenyl)-3,6-diethyl-5-(1-ethylbutoxy)- (9CI) (CA INDEX NAME)




RN 355836-67-8 CAPLUS
CN Pyrazinamine, 5-(4-(1,3-dioxolan-2-yl)-2,6-dimethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-68-9 CAPLUS
CN Pyrazinamine, 5-(4-ethoxy-2,6-dimethoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-69-0 CAPLUS
CN Pyrazinamine, 5-(2,6-dimethoxy-4-methylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-74-7 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2-methoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-75-8 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(1-methylethoxy)phenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-76-9 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(1-ethylpropoxy)phenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-77-0 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(1-ethylpropoxy)phenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-78-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)




RN 355836-80-5 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-5-(4-fluoro-2-methoxyphenyl)-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)




RN 355836-81-6 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)




RN 355836-82-7 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(2-ethyl-4-methoxyphenyl)-6-(1-propylbutoxy)- (9CI) (CA INDEX NAME)




RN 355836-87-2 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(2-methoxyethoxy)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-88-3 CAPLUS
CN Pyrazinamine, 5-[4-(difluoromethoxy)-2-methoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-89-4 CAPLUS
CN Pyrazinamine, 5-[[4-(dimethylamino)methyl]-2-methoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-90-7 CAPLUS
CN Benzenemethanol, 4-[5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazinyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-83-8 CAPLUS
CN Pyrazinamine, 5-[4-ethoxy-2-(1-methylethoxy)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-84-9 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(1-ethylpropoxy)phenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-85-0 CAPLUS
CN Pyrazine, 2-[2-chloro-4-(trifluoromethyl)phenyl]-3,6-diethyl-5-(1-ethylbutoxy)- (9CI) (CA INDEX NAME)




RN 355836-86-1 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-5-[4-(1-fluoroethyl)-2,6-dimethoxyphenyl]-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-91-8 CAPLUS
CN Pyrazinamine, 5-[4-(difluoromethoxy)-2-methoxyphenyl]-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-92-9 CAPLUS
CN Pyrazine, 2-[2-chloro-4-(propoxy)phenyl]-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




RN 355836-93-0 CAPLUS
CN Pyrazine, 2-[2-chloro-4-(cyclopropylmethoxy)phenyl]-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




RN 355836-94-1 CAPLUS
CN Pyrazine, 2-[2-chloro-4-(2-fluoroethoxy)phenyl]-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




RN 355836-95-2 CAPLUS
CN Pyrazinamine, N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(1-methylethoxy)phenyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-96-3 CAPLUS
CN Pyrazine, 2-[4-[[[(1,1-dimethylethyl)dimethylsilyloxy]-2-(1-methylethoxy)phenyl]-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




RN 355836-97-4 CAPLUS
CN Pyrazine, 2-[4-ethoxy-2-methoxyphenyl]-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




RN 355836-98-5 CAPLUS
CN Pyrazine, 2-[2,6-dimethoxyphenyl]-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




RN 355837-04-6 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(1-ethylpropoxy)-6-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 355837-06-8 CAPLUS
CN Pyrazinamine, 6-chloro-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355837-07-9 CAPLUS
CN Pyrazine, 2-[4-butoxy-2-chlorophenyl]-3,6-diethyl-5-(1-ethylbutoxy)- (9CI) (CA INDEX NAME)




RN 355837-08-0 CAPLUS
CN Pyrazinamine, N-(1-ethylbutyl)-6-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355836-99-6 CAPLUS
CN Phenol, 4-[3-ethyl-5-[(1-ethylpropyl)amino]-6-methoxyphenyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 355837-00-2 CAPLUS
CN Pyrazinamine, 6-ethyl-N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355837-01-3 CAPLUS
CN Pyrazine, 2-[4-[[[(1,1-dimethylethyl)dimethylsilyloxy]-2-(1-methylethoxy)phenyl]-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




RN 355837-03-5 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(1-ethylpropoxy)-6-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 355837-09-1 CAPLUS
CN Pyrazine, 2-[4-[[[(1,1-dimethylethyl)dimethylsilyloxy]-2-ethoxyphenyl]-3,6-diethyl-5-(1-ethylpropoxy)- (9CI) (CA INDEX NAME)




RN 355837-10-4 CAPLUS
CN Pyrazinamine, N-(6-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]pyrazinyl)- (9CI) (CA INDEX NAME)




RN 355837-12-6 CAPLUS
CN Pyrazine, 2,5-diethyl-3-(1-ethylpropoxy)-6-[2-(1-methylethoxy)-4-propoxyphenyl]- (9CI) (CA INDEX NAME)




RN 355837-14-8 CAPLUS
CN Pyrazinamine, 5-(4-chloro-2,6-dimethoxyphenyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355837-23-9 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-(dimethylamino)phenyl)-3,6-diethyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 355837-24-0 CAPLUS
CN Pyrazinamine, 2-(4-chloro-2,6-dimethoxyphenyl)-3-ethyl-5-(1-ethylpropoxy)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355837-25-1 CAPLUS
CN Pyrazinamine, 5-ethyl-3-(1-ethylpropoxy)-6-(2-methoxy-5-(trifluoromethoxy)phenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 355839-94-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)


(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)




RN 355836-28-1 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 355836-29-2 CAPLUS
CN Pyrazinamine, 6-chloro-3-ethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355836-34-9 CAPLUS
CN Pyrazinamine, 6-methoxy-N-[(4-methoxyphenyl)methyl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355836-35-0 CAPLUS
CN Pyrazinamine, 3-bromo-6-methoxy-N-[(4-methoxyphenyl)methyl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




IT 355836-12-3F 355836-19-0F 355836-20-3P
355836-27-0F 355836-28-1F 355836-29-2P
355836-34-9F 355836-35-0F 355836-36-1P
355836-37-2P
EL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted arylpyrazines and their binding with CRP1 receptors)


RN 355836-12-3 CAPLUS
CN 2(1H)-Pyridinone, 3-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-6-hydroxy- (9CI) (CA INDEX NAME)




RN 355836-19-0 CAPLUS
CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-20-3 CAPLUS
CN Pyrazinamine, 3-bromo-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-27-0 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355836-36-1 CAPLUS
CN Pyrazinamine, 3-ethyl-6-methoxy-N-[(4-methoxyphenyl)methyl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355836-37-2 CAPLUS
CN Pyrazinamine, 3-ethyl-6-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




LS ANSWER 27 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:472472 CAPLUS
DOCUMENT NUMBER: 135:81972
TITLE: Formulations of adenosine A1 agonists
INVENTOR(S): Bountra, Charanjit; Clayton, Nicholas; Maughan, Naylor, Alan
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045684	A2	20010528	WO 2000-GB4888	20001219
WO 2001045684	A3	20020314		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BE, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU,				

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM
 EW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1239880 A2 20020918 EP 2000-985631 20001219
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, PT, RO, SK, CY, AL, TR
 JP 2003518042 T2 20030603 JP 2001-546423 20001219
 US 2003008842 A1 20030109 US 2002-168196 20020618
 GB 1999-30079 A 19991220
 WO 2000-GB4888 W 20001219

AB A method of treating conditions associated with pain and alleviating the
 symptoms associated with it comprises administering to a mammal an adenosine
 A1 agonist or a salt or solvate and a sodium channel blocker. The present
 invention also provides pharmaceutical formulations and patient packs
 comprising the combinations. Thus, (2S,3S,4R,5R)-2-(5-tert-butyl-
 (1,3,4)oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)parin-9-
 yl]tetrahydrofuran-3,4-diol was prepared in a series of steps by the
 reaction of (3aS,4S,6R,6aR)-6-(6-chloropurin-9-yl)-2,2-
 dimethyltetrahydrofuro[3,4-d[1,3]dioxole-4-carboxylic acid with
 2,2-dimethylpropionic acid hydrazide followed by the cyclization of the
 resulting compound, and subsequent treatment with 4-chloro-2-fluorocaniline
 and deprotection.
 IT 212778-82-0 259828-60-9
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (formulations of adenosine A1 agonists)
 EN 212778-82-0 CAPLUS
 CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




EN 259828-60-9 CAPLUS
 CN Pyrazinecarboxamide, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




LS ANSWER 28 OF 51 CAPLUS COPYRIGHT 2005 ACS ON STN
 ACCESSION NUMBER: 2001:114448 CAPLUS
 DOCUMENT NUMBER: 135:118854
 TITLE: Catechol derivatives of aminopyrazine and cell
 protection against uvb-induced mortality

AUTHOR(S): Cavalier, J.-F.; Burton, M.; Dussart, F.; Marchand,
 C.; Rees, J.-F.; Marchand-Brynmart, J.
 CORPORATE SOURCE: Unite de Chimie Organique et Medicinale, Universite
 Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
 SOURCE: Bioorganic & Medicinal Chemistry (2001), 9(4),
 1037-1044
 CODEN: BMCEP; ISSN: 0968-0896
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A series of 5-aryl- and 3,5-bis-aryl-2-amino-1,4-pyrazine derivs. and
 related indolopyrazinones has been synthesized. The aryl groups of
 which are catechol and/or phenol substituents. These compds., tested
 against human keratinocyte cells stressed by UVB irradiation, showed high
 antioxidative properties. One compound was more active than EXCG/ECG
 (green tea extract) in reducing cell mortality.
 IT 350819-15-7P
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
 effector, except adverse); BSU (Biological study, unclassified); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (catechol derivs. of aminopyrazine and cell protection against UVB)
 EN 350819-15-7 CAPLUS
 CN 1,3-Benzoxazole, 4-(5-aminopyrazinyl)- (9CI) (CA INDEX NAME)



IT 154616-04-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (catechol derivs. of aminopyrazine and cell protection against UVB)
 EN 154616-04-3 CAPLUS
 CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 29 OF 51 CAPLUS COPYRIGHT 2005 ACS ON STN
 ACCESSION NUMBER: 2001:78155 CAPLUS
 DOCUMENT NUMBER: 134:131548
 TITLE: Preparation of tricyclic compounds as allergy
 inhibitors, immunosuppressants, and IgE production
 inhibitors
 INVENTOR(S): Tanisoto, Norihiko; Inagaki, Masanao
 PATENT ASSIGNEE(S): Shimogaki & Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 363 pp.
 CODEN: PIKXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese




FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007401	A1	20010201	WO 2000-JP4726	20000714
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM				
EW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000060160	A5	20010213	AU 2000-00160	20000714
PRIORITY APPL. INFO.: JP 1999-209298 A 19990723				
JP 1999-211702 A 19990723				
WO 2000-JP4726 W 20000714				

OTHER SOURCE(S): MARPAT 134:131548
 GI



AB The title compds. I (A, B and C are each an aromatic carbo- or hetero-cycle
 or the like, with the proviso that when A is an optionally substituted
 five-membered heterocycle, W1 is a bond, the same applying in the case of
 B and W2 and that of C and W3; X and Y are each O, NH, or the like; Y is
 lower alkyl, lower alkenyl, or the like; V1 and V2 are each a single bond
 or the like; Ra and Rb are each hydrogen, lower alkyl, lower alkenyl,
 or the like; further details on Ra and Rb are given; n is 0 to 2) are prepared
 Several compds. of this invention at 40 mg/kg/day orally for 10 days
 suppressed the production of IgE in a mouse model. Formulations are given.
 IT 321982-04-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tricyclic compds. as allergy inhibitors, immunosuppressants,
 and IgE production inhibitors)
 EN 321982-04-1 CAPLUS
 CN 2-Propanone, O-[5-(2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-
 butenyl)amino][1,1'-biphenyl]-4-yl)pyrazinyl]oxime (9CI) (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 30 OF 51 CAPLUS COPYRIGHT 2005 ACS ON STN
 ACCESSION NUMBER: 2000:456951 CAPLUS
 DOCUMENT NUMBER: 133:79433
 TITLE: Apparatus and process for preparing crystalline
 particles
 INVENTOR(S): Lancaster, Robert William; Singh, Hardev; Theophilus,
 Andrew Lewis
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 49 pp.
 CODEN: PIKXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038811	A1	20000706	WO 1999-GB4368	19991222
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM				
EW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6482438	B1	20021119	US 1999-348948	19990707
CA 2356897	AA	20000706	CA 1999-2356897	19991222
BR 9916587	A	20010925	BR 1999-16587	19991222
EP 1144065	A1	20011017	EP 1999-962413	19991222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, IE, SI, FI				
TR 200101845	T2	20011022	TR 2001-200101845	19991222
JP 2002533205	T2	20021008	JP 2000-590755	19991222
JP 3580850	B2	20041110		
NZ 512400	A	20030228	NZ 1999-512400	19991222
AU 759980	B2	20030501	AU 2000-18771	19991222
NO 2001003039	A	20010822	NO 2001-3039	20010619
ZA 2001005070	A	20020920	ZA 2001-5070	20010620
PRIORITY APPL. INFO.: GB 1998-28721 A 19981224				
WO 1999-GB4368 W 19991222				

AB A process for preparing crystalline particles, especially particles of a
 pharmaceutical
 or carrier substance suitable for inhalation therapy is described, in
 addition to an apparatus for the preparation of such particles. An example is
 give for
 distribution of particles of crystalline fluticasone propionate.
 IT 212778-82-0
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
 use); BIOL (Biological study); PROC (Process); USES (Uses)
 (apparatus and process for preparing crystalline particles)
 EN 212778-82-0 CAPLUS
 CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 31 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2000:335409 CAPLUS
 DOCUMENT NUMBER: 132:334474
 TITLE: Preparation of spiroindolines as Y5 receptor antagonists
 INVENTOR(S): Gao, Ying-chao; Macneil, Douglas J.; Yang, Lihui; Morin, Nancy R.; Fukami, Takehiro; Kanatani, Akio; Fukuroda, Takahiro; Ishii, Yasuyuki; Morin, Masaki
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.; et al.
 SOURCE: PCT Int. Appl., 130 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027845	A1	20000518	WO 1999-US26447	19991108
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, EG, GE, GM, KE, LS, MG, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CO, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2350714	AA	20000518	CA 1999-2350714	19991108
US 6191160	B1	20010220	US 1999-436120	19991108
EP 1129089	A1	20010905	EP 1999-971808	19991108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 756797	B2	20030123	AU 2000-14732	19991108
US 6313298	B1	20011106	US 2000-656698	20000907
US 2002058013	A1	20020516	US 2001-896940	20010629
US 6495559	B2	20021217	US 2002-228250	20030826
US 6638942	B1	20031028	US 2003-624414	20030721
US 2004063942	A1	20040401	US 1998-107835P	P 19981110
PRIORITY APPLN. INFO:			US 1999-436120	A3 19991108
			WO 1999-US26447	W 19991108
			US 2000-656698	A3 20000907
			US 2001-896940	A3 20010629
			US 2002-228250	A3 20020826

OTHER SOURCE(S): MARPAT 132:334474
 GI




AB The title compds. I [V, W, X, Z = CH, N; R1 = H, alkyl, etc.; R2 = CHO, etc.; R3 = H, alkyl; Ar = aryl, heteroaryl; R4, R5 = H, nitro, etc.] are prepared I are useful in the treatment of obesity and the complications associated therewith. 1-Methanesulfonyl-N-(5-phenyl-2-pyrazinyl)spiro[indoline-3,4'-piperidine]-1'-carboxamide at 3 mg/kg suppressed bovine pancreatic polypeptide-induced food intake in rats. Formulations are given.
 IT 268536-93-2F 268536-94-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of spiroindolines as Y5 receptor antagonists)
 RN 268536-93-2 CAPLUS
 CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, 1,2-dihydro-N-[5-(2-methoxyphenyl)pyrazinyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



PAGE 1-A

RN 268536-94-3 CAPLUS
 CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, N-[5-(2-chlorophenyl)pyrazinyl]-1,2-dihydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 32 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2000:161266 CAPLUS
 DOCUMENT NUMBER: 132:194395
 TITLE: Preparation of pyrazines as anticonvulsants
 INVENTOR(S): Cox, Brian; Healy, Mark Patrick; Wild, Deborah
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012488	A1	20000309	WO 1999-EP6248	19990826
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, EG, GE, GM, KE, LS, MG, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CO, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				




AB The title compds. I; R1 = Ph substituted by one or more halogen atoms; R2 = NH2; R3 = NH2, H; R4 = C(NH2)2, C(NH2)2NRaRb (wherein X = O, S, Y = O-2; Ra, Rb = H, alkyl; NRaRb = (un)substituted saturated 5-6 membered heterocycle containing one or two N atoms), useful in the treatment of CNS diseases such as epilepsy, were prepared and formulated. E.g., a multi-step synthesis of pyrazine I [R1 = 2,3,5-trichlorophenyl; R2 = R3 = NH2; R4 = CONH2] was given. Compds. I showed ED50 of 1.4 mg/kg compared to 6.1 mg/kg for lamotrigine with a therapeutic index (ratio of the ataxia ED50 and MES ED50) of 21.6 compared to 3.3 for lamotrigine.
 IT 259828-60-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrazines as anticonvulsants)
 RN 259828-60-9 CAPLUS
 CN Pyrazinecarboxamide, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




IT 259828-61-0P 259828-62-1P 259828-63-2P
259828-65-4P 259828-67-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazines as anticonvulsants)
RN 259828-61-0 CAPLUS
CN Pyrazinecarboxamide, 3,5-diamino-N-methyl-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 259828-62-1 CAPLUS
CN Pyrazinecarboxamide, 3,5-diamino-N-ethyl-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 259828-63-2 CAPLUS
CN Pyrazinecarboxamide, 3,5-diamino-N-(1-methylethyl)-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 259828-65-4 CAPLUS
CN Pyrazinecarboxamide, 3,5-diamino-N,N-dimethyl-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 259828-67-6 CAPLUS
CN Pyrazinecarboxamide, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



IT 212778-82-0F 212779-13-0F 212779-41-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazines as anticonvulsants)
RN 212778-82-0 CAPLUS
CN 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 212779-13-0 CAPLUS
CN Pyrazinecarbonitrile, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 212779-41-4 CAPLUS
CN 2,6-Pyrazinediamine, 3-bromo-5-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:495259 CAPLUS

DOCUMENT NUMBER: 131:129907

TITLE: Preparation and formulation of tricyclic compounds as

immunosuppressants and allergy inhibitors

INVENTOR(S): Tanimoto, Norihiko; Hasegawa, Yasushi; Haga, Nobuhiro

PATENT ASSIGNOR(S): Shionogi & Co., Ltd., Japan

SOURCE: PCT Int. Appl., 298 pp.

CODEN: PIKMD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9938829	A1	19990805	WO 1999-JP297	19990126
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,			

MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, EO, KZ, MD, RU, TJ, TM, RW, GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GR, GN, GW, ML, MR, NE, NG, SN, TD, TG

CA 2318368	AA	19990805	CA 1999-2318368	19990126
AU 9919827	A1	19990816	AU 1999-19827	19990126
AU 742641	B2	20020110		
EP 1052238	A1	20001115	EP 1999-90676	19990126
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 9908539	A	20001205	BR 1999-0539	19990126
TR 200002225	T2	20001221	TR 2000-200002225	19990126
NZ 506101	A	20000430	NZ 1999-506101	19990126
RU 2216533	C2	20001120	RU 2000-121556	19990126
NO 200003706	A	20000514	NO 2000-3706	20000719
US 6562817	B1	20000513	US 2000-600790	20000721
PRIORITY APPLN. INFO.:			JP 1998-15554	A 19980128
			WO 1999-JP297	W 19990126

OTHER SOURCE(S): MARPAT 131:129907
OI




AB The title compds. I [each of ring A, ring B and ring C is independently a substituted or unsubstituted aromatic ring or a substituted or unsubstituted five- or six-membered heterocycle which may be condensed with a benzene ring; when ring A, ring B and/or ring C is a substituted or unsubstituted five-membered heterocycle, W1, W2 and/or W3 represents a bond; X is O or NR1 (where R1 is hydrogen, a lower alkyl or the like); Y is hydrogen, a lower alkyl, a lower alkenyl or the like; one of V1 and V2 is a single bond and the other is a single bond, O, etc.] are prepared. The title compound I in vitro showed IC50 of 400 ng/mL against the growth of mouse B1A cells. The inhibiting activities of compds. of this invention against the production of IgE were also demonstrated.


IT 234428-40-1F 234428-41-2F 234428-42-3P
234428-43-4F 234428-44-5F 234428-45-6P
234428-46-7F 234428-47-8F 234428-48-9P
234428-49-0F 234428-50-1F 234428-51-2P
234428-52-3F 234428-53-4F 234428-54-5P
234428-55-6F 234428-56-7F 234428-57-8P
234428-58-9F 234428-59-0F 234428-60-1P
234428-61-2F 234428-62-3P 234428-63-4P
234428-64-5F 234428-65-6F 234428-66-7P
234428-67-8F 234428-68-9F 234428-69-0P
234428-70-1F 234428-71-2P 234428-72-3P
234428-73-4F 234428-74-5F 234428-75-6P
234428-76-7F 234428-77-8F 234428-78-9P
234428-79-0F 234428-80-1F 234428-81-2P
234428-82-3F 234428-83-4F 234428-84-5P
234428-85-6F 234428-86-7F 234428-87-8P
234428-88-9F 234428-89-0F 234428-90-1P
234428-91-2F 234428-92-3F 234428-93-4P
234428-94-5F 234428-95-6F 234428-96-7P
234428-97-8F 234428-98-9F 234428-99-0P
234428-100-1F 234428-101-2F 234428-102-3P
234428-103-4F 234428-104-5F 234428-105-6P
234428-106-7F 234428-107-8F 234428-108-9P
234428-109-0F 234428-110-1F 234428-111-2P
234428-112-3F 234428-113-4F 234428-114-5P
234428-115-6F 234428-116-7F 234428-117-8P
234428-118-9F 234428-119-0F 234428-120-1P
234428-121-2F 234428-122-3F 234428-123-4P
234428-124-5F 234428-125-6F 234428-126-7P
234428-127-8F 234428-128-9F 234428-129-0P
234428-130-1F 234428-131-2F 234428-132-3P
234428-133-4F 234428-134-5F 234428-135-6P
234428-136-7F 234428-137-8F 234428-138-9P
234428-139-0F 234428-140-1F 234428-141-2P
234428-142-3F 234428-143-4F 234428-144-5P
234428-145-6F 234428-146-7F 234428-147-8P
234428-148-9F 234428-149-0F 234428-150-1P
234428-151-2F 234428-152-3F 234428-153-4P
234428-154-5F 234428-155-6F 234428-156-7P
234428-157-8F 234428-158-9F 234428-159-0P
234428-160-1F 234428-161-2F 234428-162-3P
234428-163-4F 234428-164-5F 234428-165-6P
234428-166-7F 234428-167-8F 234428-168-9P
234428-169-0F 234428-170-1F 234428-171-2P
234428-172-3F 234428-173-4F 234428-174-5P
234428-175-6F 234428-176-7F 234428-177-8P
234428-178-9F 234428-179-0F 234428-180-1P
234428-181-2F 234428-182-3F 234428-183-4P
234428-184-5F 234428-185-6F 234428-186-7P
234428-187-8F 234428-188-9F 234428-189-0P
234428-190-1F 234428-191-2F 234428-192-3P
234428-193-4F 234428-194-5F 234428-195-6P
234428-196-7F 234428-197-8F 234428-198-9P
234428-199-0F 234428-200-1F 234428-201-2P
234428-202-3F 234428-203-4F 234428-204-5P
234428-205-6F 234428-206-7F 234428-207-8P
234428-208-9F 234428-209-0F 234428-210-1P
234428-211-2F 234428-212-3F 234428-213-4P
234428-214-5F 234428-215-6F 234428-216-7P
234428-217-8F 234428-218-9F 234428-219-0P
234428-220-1F 234428-221-2F 234428-222-3P
234428-223-4F 234428-224-5F 234428-225-6P
234428-226-7F 234428-227-8F 234428-228-9P
234428-229-0F 234428-230-1F 234428-231-2P
234428-232-3F 234428-233-4F 234428-234-5P
234428-235-6F 234428-236-7F 234428-237-8P
234428-238-9F 234428-239-0F 234428-240-1P
234428-241-2F 234428-242-3F 234428-243-4P
234428-244-5F 234428-245-6F 234428-246-7P
234428-247-8F 234428-248-9F 234428-249-0P
234428-250-1F 234428-251-2F 234428-252-3P
234428-253-4F 234428-254-5F 234428-255-6P
234428-256-7F 234428-257-8F 234428-258-9P
234428-259-0F 234428-260-1F 234428-261-2P
234428-262-3F 234428-263-4F 234428-264-5P
234428-265-6F 234428-266-7F 234428-267-8P
234428-268-9F 234428-269-0F 234428-270-1P
234428-271-2F 234428-272-3F 234428-273-4P
234428-274-5F 234428-275-6F 234428-276-7P
234428-277-8F 234428-278-9F 234428-279-0P
234428-280-1F 234428-281-2F 234428-282-3P
234428-283-4F 234428-284-5F 234428-285-6P
234428-286-7F 234428-287-8F 234428-288-9P
234428-289-0F 234428-290-1F 234428-291-2P
234428-292-3F 234428-293-4F 234428-294-5P
234428-295-6F 234428-296-7F 234428-297-8P
234428-298-9F 234428-299-0F 234428-300-1P
234428-301-2F 234428-302-3F 234428-303-4P
234428-304-5F 234428-305-6F 234428-306-7P
234428-307-8F 234428-308-9F 234428-309-0P
234428-310-1F 234428-311-2F 234428-312-3P
234428-313-4F 234428-314-5F 234428-315-6P
234428-316-7F 234428-317-8F 234428-318-9P
234428-319-0F 234428-320-1F 234428-321-2P
234428-322-3F 234428-323-4F 234428-324-5P
234428-325-6F 234428-326-7F 234428-327-8P
234428-328-9F 234428-329-0F 234428-330-1P
234428-331-2F 234428-332-3F 234428-333-4P
234428-334-5F 234428-335-6F 234428-336-7P
234428-337-8F 234428-338-9F 234428-339-0P
234428-340-1F 234428-341-2F 234428-342-3P
234428-343-4F 234428-344-5F 234428-345-6P
234428-346-7F 234428-347-8F 234428-348-9P
234428-349-0F 234428-350-1F 234428-351-2P
234428-352-3F 234428-353-4F 234428-354-5P
234428-355-6F 234428-356-7F 234428-357-8P
234428-358-9F 234428-359-0F 234428-360-1P
234428-361-2F 234428-362-3F 234428-363-4P
234428-364-5F 234428-365-6F 234428-366-7P
234428-367-8F 234428-368-9F 234428-369-0P
234428-370-1F 234428-371-2F 234428-372-3P
234428-373-4F 234428-374-5F 234428-375-6P
234428-376-7F 234428-377-8F 234428-378-9P
234428-379-0F 234428-380-1F 234428-381-2P
234428-382-3F 234428-383-4F 234428-384-5P
234428-385-6F 234428-386-7F 234428-387-8P
234428-388-9F 234428-389-0F 234428-390-1P
234428-391-2F 234428-392-3F 234428-393-4P
234428-394-5F 234428-395-6F 234428-396-7P
234428-397-8F 234428-398-9F 234428-399-0P
234428-400-1F 234428-401-2F 234428-402-3P
234428-403-4F 234428-404-5F 234428-405-6P
234428-406-7F 234428-407-8F 234428-408-9P
234428-409-0F 234428-410-1F 234428-411-2P
234428-412-3F 234428-413-4F 234428-414-5P
234428-415-6F 234428-416-7F 234428-417-8P
234428-418-9F 234428-419-0F 234428-420-1P
234428-421-2F 234428-422-3F 234428-423-4P
234428-424-5F 234428-425-6F 234428-426-7P
234428-427-8F 234428-428-9F 234428-429-0P
234428-430-1F 234428-431-2F 234428-432-3P
234428-433-4F 234428-434-5F 234428-435-6P
234428-436-7F 234428-437-8F 234428-438-9P
234428-439-0F 234428-440-1F 234428-441-2P
234428-442-3F 234428-443-4F 234428-444-5P
234428-445-6F 234428-446-7F 234428-447-8P
234428-448-9F 234428-449-0F 234428-450-1P
234428-451-2F 234428-452-3F 234428-453-4P
234428-454-5F 234428-455-6F 234428-456-7P
234428-457-8F 234428-458-9F 234428-459-0P
234428-460-1F 234428-461-2F 234428-462-3P
234428-463-4F 234428-464-5F 234428-465-6P
234428-466-7F 234428-467-8F 234428-468-9P
234428-469-0F 234428-470-1F 234428-471-2P
234428-472-3F 234428-473-4F 234428-474-5P
234428-475-6F 234428-476-7F 234428-477-8P
234428-478-9F 234428-479-0F 234428-480-1P
234428-481-2F 234428-482-3F 234428-483-4P
234428-484-5F 234428-485-6F 234428-486-7P
234428-487-8F 234428-488-9F 234428-489-0P
234428-490-1F 234428-491-2F 234428-492-3P
234428-493-4F 234428-494-5F 234428-495-6P
234428-496-7F 234428-497-8F 234428-498-9P
234428-499-0F 234428-500-1F 234428-501-2P
234428-502-3F 234428-503-4F 234428-504-5P
234428-505-6F 234428-506-7F 234428-507-8P
234428-508-9F 234428-509-0F 234428-510-1P
234428-511-2F 234428-512-3F 234428-513-4P
234428-514-5F 234428-515-6F 234428-516-7P
234428-517-8F 234428-518-9F 234428-519-0P
234428-520-1F 234428-521-2F 234428-522-3P
234428-523-4F 234428-524-5F 234428-525-6P
234428-526-7F 234428-527-8F 234428-528-9P
234428-529-0F 234428-530-1F 234428-531-2P
234428-532-3F 234428-533-4F 234428-534-5P
234428-535-6F 234428-536-7F 234428-537-8P
234428-538-9F 234428-539-0F 234428-540-1P
234428-541-2F 234428-542-3F 234428-543-4P
234428-544-5F 234428-545-6F 234428-546-7P
234428-547-8F 234428-548-9F 234428-549-0P
234428-550-1F 234428-551-2F 234428-552-3P
234428-553-4F 234428-554-5F 234428-555-6P
234428-556-7F 234428-557-8F 234428-558-9P
234428-559-0F 234428-560-1F 234428-561-2P
234428-562-3F 234428-563-4F 234428-564-5P
234428-565-6F 234428-566-7F 234428-567-8P
234428-568-9F 234428-569-0F 234428-570-1P
234428-571-2F 234428-572-3F 234428-573-4P
234428-574-5F 234428-575-6F 234428-576-7P
234428-577-8F 234428-578-9F 234428-579-0P
234428-580-1F 234428-581-2F 234428-582-3P
234428-583-4F 234428-584-5F 234428-585-6P
234428-586-7F

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic compds. as immunosuppressants and allergy inhibitors)


RN 234428-40-1 CAPLUS
CN Pyrazinamine, 5-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy] [1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234428-41-2 CAPLUS
CN Pyrazinamine, 5-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy] [1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234428-42-3 CAPLUS
CN Pyrazinamine, N-cyclohexyl-5-[2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy] [1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234428-43-4 CAPLUS
CN Pyrazinamine, N-cyclohexyl-5-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy] [1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234428-44-5 CAPLUS




RN 234428-49-0 CAPLUS
CN Pyrazinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy] [1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234428-50-3 CAPLUS
CN Pyrazinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy] [1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234428-51-4 CAPLUS
CN Pyrazinamine, 5-[4'-amino-2,3,5,6-tetramethyl [1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234428-52-5 CAPLUS
CN Pyrazinamine, N-(3-methyl-2-butenyl)-5-[2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)amino] [1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


CN Pyrazinamine, 5-[2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy] [1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234428-45-6 CAPLUS
CN Pyrazinamine, 5-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy] [1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234428-46-7 CAPLUS
CN Pyrazinamine, 5-[2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino] [1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234428-47-8 CAPLUS
CN Pyrazinamine, 5-[4'-[bis(3-methylbutyl)amino]-2,5-dimethyl [1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234428-48-9 CAPLUS
CN [1,1'-Biphenyl]-4-amine, 2',3',5',6'-tetramethyl-N-(3-methyl-2-butenyl)-4'-[5-[(3-methyl-2-butenyl)oxy]pyrazinyl]- (9CI) (CA INDEX NAME)




RN 234428-53-6 CAPLUS
CN Pyrazinamine, 5-[3'-fluoro-2,5-dimethoxy-3,6-dimethyl-4'-[(3-methyl-2-butenyl)oxy] [1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234428-60-5 CAPLUS
CN 2[1H]-Pyrazinone, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy] [1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234428-20-0 CAPLUS
CN Pyrazinamine, 5-[2,5-dimethoxy-3,6-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]phenyl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234428-21-1 CAPLUS
CN Pyrazinamine, 5-[2,5-dimethoxy-3,6-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]phenyl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 212779-07-2 CAPLUS
 CN Propanamide, N-[6-amino-3-(2,3,5-trichlorophenyl)pyrazinyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 212779-09-4 CAPLUS
 CN Cyclopropanecarboxamide, N-[6-amino-3-(2,3,5-trichlorophenyl)pyrazinyl]- (9CI) (CA INDEX NAME)




RN 212779-13-0 CAPLUS
 CN Pyrazinecarbonitrile, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 212779-17-4 CAPLUS
 CN 2,6-Pyrazinediamine, 3-methyl-5-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 212779-39-0 CAPLUS
 CN Cyclopropanecarboxamide, N-[6-(acetylamino)-3-(2,3,5-trichlorophenyl)pyrazinyl]- (9CI) (CA INDEX NAME)





RN 212779-41-4 CAPLUS
 CN 2,6-Pyrazinediamine, 3-bromo-5-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 212779-42-5 CAPLUS
 CN Pyrazinecarboxaldehyde, 3,5-diamino-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 212779-43-4 CAPLUS
 CN Benzenesulfonic acid, 4-methyl-, [(3,5-diamino-6-(2,3,5-trichlorophenyl)pyrazinyl)methylene]hydrazide (9CI) (CA INDEX NAME)




IT 212779-29-8F 212779-35-6F 212779-38-9P
 212779-39-0F 212779-41-4F 212779-42-5P
 212779-43-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazines as anticonvulsants)


RN 212779-29-8 CAPLUS
 CN Acetamide, N-[6-amino-5-(2,3,5-trichlorophenyl)pyrazinyl]- (9CI) (CA INDEX NAME)



RN 212779-35-6 CAPLUS
 CN Acetamide, N-[6-amino-5-(2,5-dichlorophenyl)pyrazinyl]- (9CI) (CA INDEX NAME)




RN 212779-38-9 CAPLUS
 CN Propanamide, N-[6-(acetylamino)-3-(2,3,5-trichlorophenyl)pyrazinyl]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1998:482779 CAPLUS
 DOCUMENT NUMBER: 129:227130
 TITLE: Bioluminescent properties of fluorinated semi-synthetic aequorins
 AUTHOR(S): Hirano, Takashi; Ohnishi, Yoshihiro; Maki, Shojiro; Niwa, Haruki; Ohashi, Mamoru
 CORPORATE SOURCE: Department of Applied Physics and Chemistry, The University of Electro-Communications, Tokyo, 182, Japan
 SOURCE: Tetrahedron Letters (1998), 39 (31), 5541-5544
 CODEN: TETLEY, ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Bioluminescent properties of semi-synthetic aequorins containing the coelenterazine analogs I (X, Y = H, F) possessing fluoro group(s) on the 6-(4-hydroxyphenyl) group match the fluorescent behavior of the phenolate anions of the corresponding fluorinated coelenteramide analogs II. This indicates that the phenolate anion of coelenteramide is the light-emitter in aequorin bioluminescence.

IT 212842-96-1P
 RL: BPR (Biological process); BSU (Biological study, unclassified); PREP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
 (preparation and bioluminescent properties of fluorinated semi-synthetic aequorins)


RN 212842-96-1 CAPLUS
 CN Benzenesulfonamide, N-[5-(2,3-difluoro-4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl]-4-hydroxy- (9CI) (CA INDEX NAME)



IT 212842-99-4P 212843-01-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and bioluminescent properties of fluorinated semi-synthetic
 aequorins)
 RN 212842-99-4 CAPLUS
 CN Pyrazinamine, 5-(2,3-difluoro-4-(phenylmethoxy)phenyl)-3-(phenylmethyl)-
 (9CI) (CA INDEX NAME)



RN 212843-01-1 CAPLUS
 CN Phenol, 4-[5-amino-6-(phenylmethyl)pyrazinyl]-2,3-difluoro- (9CI) (CA
 INDEX NAME)




REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 36 OF 51 CAPLUS COPYRIGHT 2005 ACS on STM
 ACCESSION NUMBER: 1997:613880 CAPLUS
 DOCUMENT NUMBER: 127:293247
 TITLE: Preparation of pyrrolopyrazines as GABA_A receptor
 ligands
 INVENTOR(S): Blum, Charles; Butchison, Alan
 PATENT ASSIGNEE(S): Neurogen Corp., USA
 SOURCE: U.S., 16 pp., Cont.-in-part of U.S. 5,606,059.
 CODEN: USYKAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5668283	A	19970916	US 1995-486595	19950607
US 5286860	A	19940215	US 1992-975409	19921112
US 5606059	A	19970225	US 1995-436252	19950512
US 5910590	A	19990608	US 1997-931648	19970916
PRIORITY APPL. INFO.:			US 1992-975409	A2 19921112
			US 1995-436252	A2 19950512
			WO 1993-US10870	W 19931110
			US 1995-486595	A1 19950607


OTHER SOURCE(S): MARPAT 127:293247
 GI



AB Fluorescent 2,3-cyanobenzofuro[2,3-b]pyrazine deriva. [I, Y, Z = H, lower
 alkyl, lower alkoxy, di(lower alkyl)amino; provided that at least one of Y
 and Z = di(lower alkyl)amino] are prepared by cyclocondensation of
 2,3-dihalo-5,6-dicyanopyrazine (II; Y = halo) with phenol deriva. (III; R
 = H, HO-protecting group; A, B = H, lower alkyl, lower alkoxy, di(lower
 alkyl)amino) under heating in solvent followed by treatment with an alkali
 or acid. Thus, 398 mg 2,3-dichloro-5,6-dicyanopyrazine was dissolved in
 50 mL toluene, followed by adding dropwise a solution of 274 mg
 3-dimethylaminophenol in 5 mL toluene, and the resulting mixture was
 refluxed for 24 h to give, after workup and alumina column chromatog., 306
 mg I (Y = H, Z = NMe₂). The latter compound showed the maximum absorbency at
 430 nm and the maximum fluorescence at 528 nm. in EtOH.


IT 173339-00-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of dicyanobenzofuro[2,3-b]pyrazine deriva. as fluorescent
 substances)

RN 173339-00-9 CAPLUS
 CN Pyrazinecarbonitrile, 5-chloro-6-(2-(dimethylamino)-6-hydroxyphenyl)-3,4-
 dihydro-3-oxo- (9CI) (CA INDEX NAME)



LS ANSWER 38 OF 51 CAPLUS COPYRIGHT 2005 ACS on STM
 ACCESSION NUMBER: 1995:541424 CAPLUS
 DOCUMENT NUMBER: 122:290892
 TITLE: Preparation of diphenylpyrazine derivatives as
 herbicides
 INVENTOR(S): Yanai, Toshiaki; Tsukamoto, Yoshihisa; Sakamoto,
 Takashi; Teramura, Masahiro; Ppomma, Toyokuni
 PATENT ASSIGNEE(S): Sanryo Co, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.
 CODEN: JKKYAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07033752	A2	19950203	JP 1993-176525	19930716



AB Title compds. [I, R = (un)substituted Ph, -thienyl, -pyridyl; R4R5 =
 (CH₂)_nCH₂CH₂ or CH₂CH₂; Z1, R1, R2, R6 = H or alkyl; Z = H₂, CO,
 CH(CH₃), alkoxycarbonylmethyl, etc.; R3 = H, (phenyl)alkyl, Ph, alkoxy,
 etc.; Z1 = NCH₃; R15 = H, halo, (phenyl)alkyl, etc.; Z2 = CH or H; n =
 0-2] were prepared. Thus, 2,5-F(MeO)C₆H₃COCHO was cyclocondensed with
 H₂NCH₂COCH₂ and the product converted in 4 steps to I [R =
 C₆H₄(OMe)F-5,2, R4R5 = (CH₂)₄]. Data for biol. activity of I were given.

IT 154032-60-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrrolopyrazines as GABA_A receptor ligands)


RN 154032-60-7 CAPLUS
 CN 2(1H)-Pyrazinone, 5-(2-fluoro-5-methoxyphenyl)-, hydrazones (9CI) (CA
 INDEX NAME)



LS ANSWER 37 OF 51 CAPLUS COPYRIGHT 2005 ACS on STM
 ACCESSION NUMBER: 1995:99369 CAPLUS
 DOCUMENT NUMBER: 124:146199
 TITLE: Preparation of 2,3-dicyanobenzofuro[2,3-b]pyrazine
 derivatives as fluorescent substances
 INVENTOR(S): Matsunaka, Masaru; Matsushima, Yoshimasa
 PATENT ASSIGNEE(S): Takasago Perfumery Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKKYAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07247288	A2	19950926	JP 1994-65424	19940310
PRIORITY APPL. INFO.:			JP 1994-65424	19940310
OTHER SOURCE(S):			CASREACT 124:146199; MARPAT 124:146199	


PRIORITY APPL. INFO.: JP 1993-176525 19930716
 OTHER SOURCE(S): MARPAT 122:290892
 GI



AB The title compds. [I, R1 = H, alkyl, alkoxy, alkenyl, aryl; R2 = alkyl
 optionally halogenated by 1-3 halogen atoms, alkoxy, alkenyl, aryl, OH,
 cyclohexyl, PhO, pyridyl, cyano, halo, PhCO, CH₂Ph, alkoxy, carbonyl,
 alkoxy, carbonyl, methoxy; R4, R5 = H, halo, alkyl, alkoxy, A = O, S(O)_n
 (wherein n = 0.1.2), NMe₂, NH, NMe; m = 0.1], which show excellent
 herbicidal activity for weeds of rice paddy such as Echinochloa crus-galli,
 broad leaf weeds, and Scirpus juncoides, are prepared. A herbicide composition
 contains I as the active ingredient. Thus, 2-hydroxy-5,6-diphenylpyrazine
 was slowly added dropwise to a suspension of NaH in DMF under ice-cooling
 followed by adding Et bromacetate dropwise and the resulting mixture was
 stirred at room temperature for 1.5 h to give 100% Et (5,6-diphenyl-2-
 pyrazinyloxy)acetate (II). II at 50 g/are inhibited the growth of E.
 crus-galli, broad leaf weed, Eleocharis acicularis, Cyperus serotinus,
 Eleocharis kuroguwai, and S. juncoides by 91-100% in potted paddy soil,
 whereas rice seedlings were not damaged.

IT 162928-08-7P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except
 adverse); BSU (Biological study, unclassified); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of diphenylpyrazine deriva. as herbicides)



RN 162928-08-7 CAPLUS
 CN Acetic acid, [(5,6-bis(2-chlorophenyl)pyrazinyl)oxy]-, ethyl ester (9CI)
 (CA INDEX NAME)



LS ANSWER 39 OF 51 CAPLUS COPYRIGHT 2005 ACS on STM
 ACCESSION NUMBER: 1994:508837 CAPLUS
 DOCUMENT NUMBER: 121:108837
 TITLE: Liquid crystalline di-, tri- and
 tetrafluorophenylpyrazines
 INVENTOR(S): Brown, John William; Bursat, Derek Thomas; O'Donovan,
 Jacqueline Patricia; Coates, David; Greenfield, Simon;
 Goulding, Mark John; Gray, George William
 PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: Brit. UK Pat. Appl., 22 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2272216	A1	19940511	GB 1992-23244	19921104
PRIORITY APPL. INFO:			GB 1992-23244	19921104
OTHER SOURCE(S):				




AB Phenylpyrazine deriva. (I; R1, R2 = (un)substituted alkyl or alkenyl; L1, L2 = H, F), useful as components of liquid-crystalline phases in liquid crystal display devices (no data), are prep. Thus, (difluorophenyl)pyrazine II was prepared from PrOCMe in 4 steps.

IT 156573-06-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as liquid crystal)

EN 156573-06-7 CAPLUS

CN Pyrazine, 2-(2,3-difluoro-4-propoxyphenyl)-5-(pentyloxy)- (9CI) (CA INDEX NAME)



L5 ANSWER 40 OF 51 CAPLUS COPYRIGHT 2005 ACS on STM

ACCESSION NUMBER: 1994:493377 CAPLUS

DOCUMENT NUMBER: 121:83377

TITLE: [Biphenyl]pyrazines for liquid crystalline media
INVENTOR(S): Brown, John William; Hurst, Derek Thomas; O'Donovan, Jacqueline Patricia; Coates, David; Greenfield, Simon; Goulding, Mark John; Gray, George William

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany



SOURCE: Brit. UK Pat. Appl., 40 pp.

CODEN: BAYXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

JP 3314397 B2 20020812 JP 1992-13167 19920120
PRIORITY APPL. INFO.: MARPAT 120:269942
OTHER SOURCE(S):
GI




AB The title compds. (I; R1 = H, C1-4 alkyl, alkoxy; R2 = H, C1-10 alkyl, N-succinimidyl; n = 1-10) are prepared I react with biol. important substances such as antigens, antibodies, hormones, drugs, drug metabolites, toxins, and alkaloids to form luminescent compds. and thus are used as reagents for luminescent anal. and chemiluminescence immunoassay (no data). Thus, iso-Pr levulinate was oxidized by SnO2 in iso-PrOH at 80° to give 50% glyoxal derivative HOCOC(CH2)2CO2CHMe2 which was cyclized with 2-amino-6-(p-methoxyphenyl)pyrazine in the presence of concentrated HCl in iso-PrOH at 70° to give a phenylimidazopyrazine derivative (II; R2 = iso-Pr). The latter compound was hydrolyzed in 3N HCl at 60° to give 60% IT (R2 = H). Adm. 9 I were prepared.

IT 154616-04-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation of, with glyoxal derivative)

EN 154616-04-3 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 42 OF 51 CAPLUS COPYRIGHT 2005 ACS on STM

ACCESSION NUMBER: 1994:245160 CAPLUS



DOCUMENT NUMBER: 120:245160

TITLE: Preparation of indolopyrazines and related compounds as brain GABAa agonists, antagonists, or inverse agonists

INVENTOR(S): Blum, Charles; Hutchison, Alan

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2271351	A1	19940413	GB 1992-21139	19921008
PRIORITY APPL. INFO:			GB 1992-21139	19921008
OTHER SOURCE(S):				



AB Biphenylpyrazines I (R1, R2 = , haloalkyl, etc.; x = 0-2) were disclosed. Also claimed were [(cyclohexyl)phenyl]pyrazines. Liquid crystal media and electrooptical devices containing I are claimed. An example compound,


IT 2-Pentyloxy-5-(4'-propyl[1,1'-biphenyl]-4-yl)pyrazine (II) was prepared

IT 156487-05-7P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as liquid crystal)

EN 156487-05-7 CAPLUS

CN Pyrazine, 2-(4-butoxy-2,3-difluorophenyl)-5-(pentyloxy)- (9CI) (CA INDEX NAME)



L5 ANSWER 41 OF 51 CAPLUS COPYRIGHT 2005 ACS on STM

ACCESSION NUMBER: 1994:269942 CAPLUS

DOCUMENT NUMBER: 120:269942

TITLE: Preparation of Cypridinide's luciferin derivatives as luminescent probes for chemiluminescence immunoassay
INVENTOR(S): Sawada, Hideo; Totani, Yoshiaki; Mitani, Motohiro; Ichikawa, Hideo; Matsumoto, Takeo
Nippon Oils & Fats Co Ltd, Japan
Jpn. Kokai Tokkyo Koho, 10 pp.

PATENT ASSIGNEE(S):

SOURCE:

CODEN: JKKXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05266976	A2	19931102	JP 1992-13167	19920120

PATENT ASSIGNEE(S): Neurogen Corp., USA

SOURCE: U.S., 17 pp.

CODEN: USXKAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5286860	A	19940215	US 1992-975409	19921112
WO 9411374	A1	19940526	WO 1993-US10870	19931110
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, RO, RU, SD, SE, SK, UA, US, VN				
EW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SP, BJ, CP, CO, CI, CM, CA, GN, ML, MR, NE, SN, TD, TG				
AU 9455526	A1	19940608	AU 1994-55526	19931110
US 5606059	A	19970225	US 1995-436252	19950512
US 5668283	A	19970916	US 1995-486595	19950607
PRIORITY APPL. INFO:			US 1992-975409	A 19921112
			WO 1993-US10870	W 19931110
			US 1995-436252	A2 19950512

OTHER SOURCE(S): MARPAT 120:245160

GI For diagram(s), see printed CA Issue.

AB Title compds. (I; ring Q = O1, Q2; n = 0-2; R1, R2 = H, alkyl; Y = various organic and inorg. substituents; W = aromatic group substituted with various organic and inorg. substituents; A = CH, N; B = (substituted) C, N; and E = H, alkyl). These compds. are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or produce thereof and are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overdose with benzodiazepine type drugs, and enhancement of alertness. Thus, glycylamide was cyclized with 2-fluoro-5-methoxyphenyl glyoxal to give 5-(2-fluoro-5-methoxyphenyl)pyrazine-2-one. This was chlorinated with POCl3 followed by condensation with hydrazine to give 2-hydrazino-5-(2-fluoro-5-methoxyphenyl)pyrazine. The latter was condensed with cyclohexanone to give the hydrazone, which was refluxed in diethylene glycol to give title compound I. I showed IC50 = 0.200 μM for binding to GABAa receptors.


IT 154032-58-3F 154032-60-7F 154032-61-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as intermediate for GABAa receptor ligand)

EN 154032-58-3 CAPLUS

CN 2(1H)-Pyrazinone, 5-(2-fluoro-5-methoxyphenyl)- (9CI) (CA INDEX NAME)



EN 154032-60-7 CAPLUS

CN 2(1H)-Pyrazinone, 5-(2-fluoro-5-methoxyphenyl)-, hydrazone (9CI) (CA INDEX NAME)


CAS MISTAKE.
REF. DOESN'T
DISCLOSE

R1, R3 = H
J, K = C.
G = O
Rx = ALKYL CS
R5 = HALO
R7 = ALKOXY
R8 = H


THIS
REFERENCE
GB2271351,
DOES NOT
DISCLOSE
THAT
COMPOUND.

EX. 2 PG
30
IS
WHAT THE
CAS -
INDEXED
COMPOUND
IS REFERRING
TO.


THERE
IS AN
INTERPOSED
PHENYLENE
RING
IN
THE REF.
COMPD.
ERROR
#REPORTED
TO CAS
6/29/05




LN 154032-61-8 CAPLUS
CN 2(1H)-Pyrazinone, 5-(2-fluoro-5-methoxyphenyl)-, cyclohexylidenehydrazono
(9CI) (CA INDEX NAME)




LN ANSWER 43 OF 51 CAPLUS COPYRIGHT 2005 ACS on STM
ACCESSION NUMBER: 1992:571380 CAPLUS
DOCUMENT NUMBER: 117:171380
TITLE: Metalation of diazines. VI. Metalation of pivaloylaminopyrazine and N-tert-butylpyrazinamide. Unusual regioselectivity in the metalation reaction.
AUTHOR(S): Turk, A.; Pie, N.; Trohay, D.; Mdzil, B.; Queguiner, G.
CORPORATE SOURCE: Lab. Chim. Org. Fine Heterocyclique, INSA, Mt. St. Aignan, 74131, Fr.
SOURCE: Journal of Heterocyclic Chemistry (1992), 29(4), 699-702
CODEN: JHYCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 117:171380
AB Metalation of (pivalamido)pyrazine and N-(t-butyl)pyrazinamide were studied. For (pivalamido)pyrazine the yields were poor and some addition products were isolated. The metalation of t-butylpyrazinamide was successful and a curious regioselectivity was highlighted.
IT 143769-10-2P, 3-benzyl-2-(pivaloylamino)-5-methylpyrazine
RL: SPN (Synthetic preparation); PREP (Preparation) (regioselective preparation of)
RN 143769-10-2 CAPLUS
CN Propanamide, 2,2-dimethyl-N-[3-(phenylmethyl)-5-(2,4,6-trimethylphenyl)pyrazinyl]- (9CI) (CA INDEX NAME)




CN Pyrazinamine, 5-(2-chlorophenyl)-6-methyl- (9CI) (CA INDEX NAME)



IT 69816-72-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and insecticidal activity of)
RN 69816-72-4 CAPLUS
CN Benzamide, 2-chloro-N-[[5-(2,4-dimethylphenyl)pyrazinyl]amino]carbonyl- (9CI) (CA INDEX NAME)




IT 69816-87-1P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
RN 69816-87-1 CAPLUS
CN Benzamide, 2-chloro-N-[[6-methyl-5-(2-methylphenyl)pyrazinyl]amino]carbonyl- (9CI) (CA INDEX NAME)




LN ANSWER 45 OF 51 CAPLUS COPYRIGHT 2005 ACS on STM
ACCESSION NUMBER: 1980:620777 CAPLUS
DOCUMENT NUMBER: 93:220777
TITLE: Substituted 2-aminopyrazines
INVENTOR(S): Baumeet, Charles J.; Emsick, Thomas L.; Hoving, Richard C.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: U.S., 11 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

LN ANSWER 44 OF 51 CAPLUS COPYRIGHT 2005 ACS on STM
ACCESSION NUMBER: 1982:35307 CAPLUS
DOCUMENT NUMBER: 96:25307
TITLE: 1-(Mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
INVENTOR(S): Niesel, John L.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: U.S., 15 pp. Cont.-in-part of U.S. Ser. No. 081,300, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4293552	A	19811006	US 1979-62393	19790731
PRIORITY APPL. INFO.:			US 1978-801300	A2 19780227



AB 2-aminopyrazines underwent an addition reaction with 2-RC6H4CONCO (R = Br, Cl) to yield the resp. ureas I [R1 = H, Cl, Me, CF3; R2 = H, CF3, Ph, halo-, methoxy-, (trifluoromethyl)-, or phenylphenyl], which exhibited insecticidal activity. Thus, 2-ClC6H4CONCO was added to 2-amino-5-(4-bromophenyl)-6-methylpyrazine and the mixture was stirred overnight to give I (R = Cl, R1 = Me, R2 = 4-BrC6H4).
IT 59489-79-1 69816-56-4 80348-73-8
RL: RCT (Reactant); RACT (Reactant or reagent) (addition reaction of, with chlorobenzoyl isocyanate)
RN 59489-79-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)





RN 69816-56-4 CAPLUS
CN Pyrazinamine, 6-methyl-5-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 80348-73-8 CAPLUS


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4211870	A	19800708	US 1979-27630	19790406
DK 8001442	A	19801007	DK 1980-1442	19800402
FI 8001056	A	19801007	FI 1980-1056	19800402
AU 8057102	A1	19801009	AU 1980-57102	19800402
FR 2453159	A1	19801031	FR 1980-7457	19800402
ER 8002079	A	19801125	ER 1980-2079	19800402
ES 490287	A1	1980516	ES 1980-490287	19800402
CS 215055	P	19820730	CS 1980-2293	19800402
CA 1157860	A1	19831129	CA 1980-349061	19800402
BE 882608	A1	19801003	BE 1980-9771	19800403
EP 18144	A1	19801029	EP 1980-301085	19800403
R1: DE, GB, NL, SE				
GB 2046751	A1	19801119	GB 1980-11363	19800403
GB 2046751	A1	19801119		
UD 150057	C	19810812	DD 1980-220207	19800403
ZA 8002005	A	19811125	ZA 1980-2005	19800403
HU 26151	O	19820528	HU 1980-817	19800403
SU 932989	A3	19820530	SU 1980-2902455	19800404
RO 79384	P	19820625	RO 1980-100722	19800404
JP 55141473	A2	19801105	JP 1980-45134	19800405
PRIORITY APPL. INFO.:			US 1979-27630	A 19790406




AB 2-Amino-5-phenylpyrazines I [n = 0, 1, 2 (R = H, halo, alkyl, CF3); R1 = H, alkyl; R2 = alkyl] were prepared from the resp. α-halobenzyl ketoximes II (X = Cl, Br) and H2NCH(R1)CN (R1 same as above); H2NCH(R1)CN were treated with II and base to yield hydroxyimino-substituted aminocetonitriles III, and the III were cyclized by polyphosphoric acid, H3PO4, or H3PO4-P2O5 at 50-140° to give I. Thus, H2NCH(R1)CN was N-alkylated by 4-BrC6H4CH(Cl)(NOH)Me and Et3N, and the III (Rn = 4-Br, R2 = Me, R1 = H) product was heated with polyphosphoric acid to give I (Rn = 4-Br, R2 = Me, R1 = H).
IT 75411-09-5F 75411-10-8F 75411-11-9P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
RN 75411-09-5 CAPLUS
CN Pyrazinamine, 5-(2-bromophenyl)-6-methyl- (9CI) (CA INDEX NAME)



EN 75411-10-8 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)-6-methyl- (9CI) (CA INDEX NAME)



EN 75411-11-9 CAPLUS
CN Benzamide, 2,6-dichloro-N-[(5-(2,4-dimethylphenyl)-6-methylpyrazinyl)amino]carbonyl- (9CI) (CA INDEX NAME)




LS ANSWER 46 OF 51 CAPLUS COPYRIGHT 2005 ACS on STM
ACCESSION NUMBER: 1979:540598 CAPLUS
DOCUMENT NUMBER: 91:140598
TITLE: 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas
INVENTOR(S): Miesel, John L.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: U.S., 19 pp.
CODEN: USYKAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4160834	A	19790710	US 1977-861733	19771219
AT 7705635	A	19800615	AT 1977-5635	19770729
AT 360800	B	19810126		
PRIORITY APPL. INFO.:			US 1974-507492	A2 19740919
			US 1975-595904	A2 19750714
			US 1977-775813	A2 19770309
			AT 1975-7146	A 19750917

GI


1)- (9CI) (CA INDEX NAME)



EN 71544-77-9 CAPLUS
CN Benzamide, 2,6-dichloro-N-[(5-(2-methylphenyl)pyrazinyl)amino]carbonyl- (9CI) (CA INDEX NAME)



EN 71544-80-4 CAPLUS
CN Benzamide, 2,6-dichloro-N-[(5-(2-chlorophenyl)pyrazinyl)amino]carbonyl- (9CI) (CA INDEX NAME)




LS ANSWER 47 OF 51 CAPLUS COPYRIGHT 2005 ACS on STM
ACCESSION NUMBER: 1979:152238 CAPLUS
DOCUMENT NUMBER: 90:152238
TITLE: 1-(Mono-o-substituted benzoyl)-3-(substituted pyrazinyl)ureas
INVENTOR(S): Miesel, John Louis; Abdulla, Riaz Fazel; Terando, Norman Henry
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Ger. Offen., 86 pp.
CODEN: GWYKMX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2826893	A1	19790118	DE 1978-2826893	19780619
US 4132956	A	19790109	US 1977-819639	19770727
IL 54928	A1	19802028	IL 1978-54928	19780615




AB Adding benzoyl isocyanates to aminopyrazines gave ureas I [R, R1 (same or different) = halo, Me, CF3; R2, R3 (same or different) = H, alkanylyl, alkoxy, haloalkyl, R4 = H, halo, alkyl, cycloalkyl, haloalkyl, R5, cyano, naphthyl, (CH2)nC6H4Zn (n = 0, 1; Z = halo, haloalkyl, alkyl, alkoxy, alkylthio, alkylsulfonyl, R5, cyano, Ph; n = 0, 1, 2, 3.), XC6H4Zn (X = O, S, SO2; Z and n as above); R5 = H, halo, Me, Et, cyano, haloalkyl], which were insecticidal. Thus, stirring 2-amino-5-chloropyrazine in cold EtOAc with 2,6-Cl2C6H3CONCO overnight gave I (R = R1 = R4 = Cl, R2 = R3 = R5 = H).
IT 59489-79-1 69816-56-4 71553-78-1


RL: RCT (Reactant), RACT (Reactant or reagent)
(addition reaction of, with benzoyl isocyanate derivative)
EN 59489-79-1 CAPLUS
CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



EN 69816-56-4 CAPLUS
CN Pyrazinamine, 6-methyl-5-(2-methylphenyl)- (9CI) (CA INDEX NAME)




EN 71553-78-1 CAPLUS
CN Pyrazinamine, 5-(2-chlorophenyl)- (9CI) (CA INDEX NAME)



IT 59489-64-4F 71544-77-9F 71544-80-4F
RL: AGR (Agricultural use), BAC (Biological activity or effector, except adverse), BSU (Biological study, unclassified), SYN (Synthetic preparation), BIOL (Biological study), PREP (Preparation), USES (Uses) (preparation and insecticidal activity of)
EN 59489-64-4 CAPLUS
CN Benzamide, 2,6-dichloro-N-[(5-(2,4-dimethylphenyl)pyrazinyl)amino]carbonyl


IL 64263	A1	19820330	IL 1978-64263	19780615
FR 2398738	A1	19790223	FR 1978-19187	19780616
FR 2398738	B1	19810508		
IN 149912	A	19820529	IN 1978-CA666	19780616
BE 868228	A1	19781219	BE 1978-8936	19780619
GB 2001053	A	19790124	GB 1978-27260	19780619
GB 2001053	B2	19820526		
AU 516505	B2	19810504	AU 1978-37249	19780619
AU 7837249	A1	19800103		
GB 2066806	A	19810715	GB 1980-19107	19780619
GB 2066806	B2	19820819		
AT 7804456	A	19811015	AT 1978-4456	19780619
AT 367046	B1	19820525		
CA 1129861	A1	19820817	CA 1978-305703	19780619
HU 23227	O	19820830	HU 1978-E1793	19780620
HU 180726	B	19830429		
RO 78069	P	19830803	RO 1978-94410	19780620
HU 29287	O	19840130	HU 1982-1470	19780620
HU 185336	B	19850128		
DK 7802793	A	19781223	DK 1978-2793	19780621
SE 7807127	A	19781223	SE 1978-7127	19780621
NL 7806678	NL	19781228	NL 1978-6678	19780621
BR 7803939	A	19790220	BR 1978-3939	19780621
ZA 7803553	A	19800227	ZA 1978-3553	19780621
CS 198104	P	19800530	CS 1978-4095	19780621
CS 198105	P	19800530	CS 1978-8519	19780621
CS 198106	P	19800530	CS 1978-8520	19780621
SU 784662	D	19810123	SU 1978-628947	19780621
CH 638506	A	19830930	CH 1978-6770	19780621
JP 54009280	A2	19790124	JP 1978-76343	19780622
ES 471057	A1	19800116	ES 1978-471057	19780622
DD 141831	C	19800521	DD 1978-206203	19780622
DD 143721	C	19800910	DD 1978-213690	19780622
PL 115711	B1	19810430	PL 1978-207831	19780622
ES 471878	A1	19790201	ES 1978-471878	19780622
CA 1103251	A1	19810616	CA 1978-308083	19780725
FR 2398739	A1	19790223	FR 1978-32550	19781117
FR 2398739	B1	19821105		
IL 64216	A1	19821231	IL 1979-64216	19790615
AT 8101716	A	19820415	AT 1981-1716	19810415
DK 8103054	A	19810709	DK 1981-3054	19810709
SE 8203206	A	19820607	SE 1982-3206	19820607
PRIORITY APPL. INFO.:			GB 1977-26093	A 19770622
			US 1977-819639	A 19770727
			IL 1978-54928	A3 19780615
			AT 1978-4456	A 19780619
			GB 1978-27260	A 19780619
			DK 1978-2793	A 19780621

GI




AB The insecticidal compds. I [R = halogen, Me, CF3; R1 = H, halogen, Me, CF3; R2 = H, Cl-6 alkyl, haloalkyl, CN, (substituted) phenylalkyl, PhO, PhS; R3 = H, Me, CN, halogen, haloalkyl; R2R3 = CH:CH:CH; X, X1 = CH, N] were prepared. Thus, 2-amino-5-(4-bromophenyl)-6-methylpyrazine reacted with


2-ClC₆H₄CONCO to give I (R = Cl, R₁ = H, R₂ = 4-BrC₆H₄, R₃ = Me, X = Y₁ = N), which at 5 ppm gave 100% kill of Spodoptera eridania larvae.
 IT 69816-72-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and insecticidal activity of)
 RN 69816-72-4 CAPLUS
 CN Benzamide, 2-chloro-N-[[[5-(2,4-dimethylphenyl)pyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




IT 69816-87-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 69816-87-1 CAPLUS
 CN Benzamide, 2-chloro-N-[[[6-methyl-5-(2-methylphenyl)pyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




IT 59489-79-1 69816-56-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with benzoyl isocyanate)
 RN 59489-79-1 CAPLUS
 CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 69816-56-4 CAPLUS
 CN Pyrazinamine, 6-methyl-5-(2-methylphenyl)- (9CI) (CA INDEX NAME)




IT 59489-79-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with dichlorobenzoyl isocyanate)
 RN 59489-79-1 CAPLUS
 CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)




LS ANSWER 49 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1978:50924 CAPLUS
 DOCUMENT NUMBER: 88:50924
 TITLE: 1-Benzoyl-3-pyrazinylureas
 PATENT ASSIGNEE(S): Eli Lilly and Co., USA
 SOURCE: Jpn. Kokai Tokkyo Koho, 24 pp.
 CODEN: JKKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 52010285	A2	19770126	JP 1976-1426	19760101
PRIORITY APPL. INFO.:			US 1975-595904	A 19750714

GI



AB I [R = H, Cl, Me, (substituted)Ph, etc.; R₁ = H, Cl, Me, Et, CN, or RR₁ = benzo; R₂ = Cl, Me] were prepared by reaction of 2-amino-5-R-6-R₁-pyrazoles (II) with benzoyl isocyanates 2,6-R₂C₆H₃CONCO III. I are agricultural insecticides. Thus, 0.25 g II (R = Ph, R₁ = H) and 0.45 g III (R₂ = Cl) in AcOEt were stirred overnight to give the corresponding I.
 IT 59489-79-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (cyclization of, with benzoyl isocyanate, benzoylpyrazinylurea derivative)



LS ANSWER 48 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1978:509584 CAPLUS
 DOCUMENT NUMBER: 89:109584
 TITLE: Insecticidal 1-(substituted benzoyl)-3-(substituted pyrazinyl)ureas
 INVENTOR(S): Miesel, John Louis
 PATENT ASSIGNEE(S): Eli Lilly and Co., USA
 SOURCE: U.S., 15 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4089397	A	19780411	US 1976-742948	19761118
US 3984137	A	19761005	US 1975-595504	19750714
AT 360800	B	19800615	AT 1977-5635	19770729
PRIORITY APPL. INFO.:			US 1974-507492	A2 19740919
			US 1975-595504	A3 19750714
			AT 1975-7146	A 19750917


GI




AB The title compds. I (R = R₁ = H, RR₁ = unsubstituted, halo, Cl-6 alkyl, C3-6 cycloalkyl NO₂, CN, Cl-4 haloalkyl-substituted benzo; R₂, R₃ = H, Cl-4 alkanylyl, Cl-3 alkoxy-carbonyl, R₄, R₅ = halo, Me, F3C) were prepared thus, 2-amino-5-chloropyrazine (II) was treated with 2,6-Cl₂C₆H₃CONCO to give 3-(5-chloro-2-pyrazinyl)-1-(2,6-dichlorobenzoyl)urea (III). II was prepared by chlorination of Me 2-amino-3-pyrazinylcarboxylate followed by hydrolysis and decarboxylation. At 50 ppm III completely controlled southern armyworm after 4 days.
 IT 59489-64-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and insecticidal activity of)
 RN 59489-64-4 CAPLUS
 CN Benzamide, 2,6-dichloro-N-[[[5-(2,4-dimethylphenyl)pyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

AB The title compds. I (R = R₁ = H, RR₁ = unsubstituted, halo, Cl-6 alkyl, C3-6 cycloalkyl NO₂, CN, Cl-4 haloalkyl-substituted benzo; R₂, R₃ = H, Cl-4 alkanylyl, Cl-3 alkoxy-carbonyl, R₄, R₅ = halo, Me, F3C) were prepared thus, 2-amino-5-chloropyrazine (II) was treated with 2,6-Cl₂C₆H₃CONCO to give 3-(5-chloro-2-pyrazinyl)-1-(2,6-dichlorobenzoyl)urea (III). II was prepared by chlorination of Me 2-amino-3-pyrazinylcarboxylate followed by hydrolysis and decarboxylation. At 50 ppm III completely controlled southern armyworm after 4 days.
 IT 59489-64-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and insecticidal activity of)
 RN 59489-64-4 CAPLUS
 CN Benzamide, 2,6-dichloro-N-[[[5-(2,4-dimethylphenyl)pyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

from
 RN 59489-79-1 CAPLUS
 CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



IT 59489-64-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and insecticidal activity of)
 RN 59489-64-4 CAPLUS
 CN Benzamide, 2,6-dichloro-N-[[[5-(2,4-dimethylphenyl)pyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)





LS ANSWER 50 OF 51 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1976:21468 CAPLUS
 DOCUMENT NUMBER: 85:21468
 TITLE: 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas
 INVENTOR(S): Miesel, John L.
 PATENT ASSIGNEE(S): Eli Lilly and Co., USA
 SOURCE: Ger. Offen., 70 pp.
 CODEN: GWXIBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2541116	A1	19760408	DE 1975-2541116	19750915
DE 2541116	C2	19850718		
IN 142286	A	19770618	IN 1975-CA1744	19750910
BE 832288	A1	19760311	BE 1975-1006877	19750911
IL 48092	A1	19790312	IL 1975-48092	19750912
AU 7594845	A1	19770324	AU 1975-84845	19750915
GB 1521714	A	19780816	GB 1975-37933	19750916
CA 1070308	A1	19800122	CA 1975-235561	19750916
NL 7510901	A	19760323	NL 1975-10901	19750917
ZA 7505945	A	19770427	ZA 1975-5945	19750917
AT 7507146	A	19771015	AT 1975-7146	19750917
CS 195710	P	19800229	CS 1975-6298	19750917
DK 7504195	A	19760320	DK 1975-4195	19750918
SE 7510474	A	19760322	SE 1975-10474	19750918
SE 426066	B	19821206		
SE 426066	C	19830317		

PL 102954	P	19790531	PL 1975-197527	19750910
PL 106054	P	19791130	PL 1975-183470	19750910
CH 617192	A	19800514	CE 1975-12147	19750910
HU 19446	O	19810220	HU 1975-E1646	19750910
HU 177200	P	19810820		
JP 51056489	A2	19760510	JP 1975-114226	19750910
ER 7506073	A	19760803	ER 1975-6073	19750910
FR-2299327	A1	19760827	FR 1975-28772	19750910
FR 2299327	B1	19760407		
DD 123341	C	19761212	DD 1975-188451	19750910
ES 441124	A1	19770616	ES 1975-441124	19750910
DD 128762	C	19771207	DD 1975-196898	19750910
SU 662011	D	19790505	SU 1975-2171811	19750910
SU 660566	D	19790430	SU 1976-2380308	19760709
AT 7705635	A	19800615	AT 1977-5635	19770729
AT 360800	B	19810126		
SE 7806517	A	19780602	SE 1978-6517	19780602
SE 420042	B	19810914		
SE 420042	C	19820107		

PRIORITY APPLN. INFO.:

GI



AB Insecticidal dichlorobenzoylureidopyrazines I [R = Cl, Ph, H, Me, Br, Et, substituted phenyl, CH₂CH₃, CMe₃; R1 = H, Me, Cl, CH₃; R1 = substituted (CH₃)₄ (29 compds.) were prepared by treating aminopyrazines II with 2,6-dichlorobenzoylurea, obtained by treating 2,6-dichlorobenzonitrile with (COCl)₂. At 1000 ppm I gave complete control of Spodoptera eridania.


IT 59489-64-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPV (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and insecticidal activity of)

RN 59489-64-4 CAPLUS

CN Benzamide, 2,6-dichloro-N-[[5-(2,4-dimethylphenyl)pyrazinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




IT 59489-79-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, with dichlorobenzoyl isocyanate)

RN 59489-79-1 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2005 ACS on STM

ACCESSION NUMBER: 1973:537092 CAPLUS

DOCUMENT NUMBER: 79:137092

TITLE: Pteridines. XXIX. Unequivocal route to 2,4-diamino-6-substituted pteridines

AUTHOR(S): Taylor, Edward C.; Perlman, Katherine L.; Kim, Young-Ho; Sword, Ian P.; Jacobi, Peter A.

CORPORATE SOURCE: Dep. Chem., Princeton Univ., Princeton, NJ, USA

SOURCE: Journal of the American Chemical Society (1973), 95(19), 6413-18

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB 2,4-Diamino-6-substituted pteridines (I) are prepared Reaction of an α-keto-aldoxime with aminomalonitrile gives 2-amino-3-cyano-5-substituted pyrazine 1-oxides which yield 2,4-diamino-6-substituted pteridine 8-oxides upon cyclization with guanidine. 2,4-Diaminopteridines are then obtained by decyrogenation of the corresponding 8-oxides, or alternately by prior decyrogenation of these pyrazine 1-oxides, followed by cyclization with guanidine. The conversion of 2-amino-3-cyano-5-methylpyrazine 1-oxide to the corresponding 1,4-dioxide, and a number of chemical transformations of this latter intermediate, are also described.


IT 50627-21-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(cyclization of, diaminopteridine from)

RN 50627-21-9 CAPLUS

CN Pyrazinecarbonitrile, 3-amino-6-(2-methoxyphenyl)-, 4-oxide (9CI) (CA INDEX NAME)



*, LOGOFF

ALL L5 QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF: (Y) N/HOLD:Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

CA SUBSCRIBER PRICE

ENTRY

SESSION

-27.01 -27.01

STM INTERNATIONAL LOGOFF AT 14:52:32 ON 29 JUN 2005